Adverse events associated with management of inflammatory bowel diseases: infections and side effects by HASH(0x7fe988d81c58)
  
Ph.D. Thesis 
 
ADVERSE EVENTS ASSOCIATED WITH MANAGEMENT OF 
INFLAMMATORY BOWEL DISEASES: INFECTIONS AND 
SIDE EFFECTS 
 
 
Anita Bálint M.D. 
 
 
 
 
Supervisor: Tamás Molnár, M.D.,Ph.D, med.habil 
 
 
 
1st Department of Medicine 
University of Szeged 
Szeged 
2014 
 
2 
 
 
 
TABLE OF CONTENTS 
1. ABBREVIATIONS .................................................................................................................. 4 
2. LIST OF FULL PAPERS RELATED TO THE SUBJECT OF THE THESIS ....................... 5 
3. LIST OF FULL PAPERS NOT RELATED TO THE SUBJECT OF THE THESIS .............. 5 
4. SUMMARY ............................................................................................................................. 8 
5. INTRODUCTION AND AIMS ............................................................................................. 11 
5.1. Keypoints in the management of IBD – infections and side effects ............................... 12 
5.2. Study I.: Role of the microorganism in the etiology and relapse of IBD ....................... 14 
5.3. Study II: Role of microorganism in the development of cutaneous lesions: a specific 
extraintestinal manifestation associated with an  infective intestinal disorders ........................ 16 
5.4. Study III: Efficacy and safety of immunisation in  immunocompromised IBD patients 17 
5.5. Study IV: How to decease steroid side effects? .............................................................. 18 
5.6. Study V: An underdiagnosed common side effects of calcineurin inhibitor therapy ..... 19 
5.7. Aims ................................................................................................................................ 20 
6. PATIENTS AND METHODS ............................................................................................... 21 
6.1. Description of methods ................................................................................................... 21 
6.1.1. Enzyme-linked immunosorbent assay .......................................................................... 21 
6.1.2. Lateral flow assay......................................................................................................... 21 
6.1.3. Microbiological examination of stool samples ............................................................ 22 
6.1.4 .Statistical analysis ........................................................................................................ 22 
6.1.5. Ethical Considerations.................................................................................................. 22 
6.2. Patients and methods of clinical studies ......................................................................... 22 
6.2.1. Study I: Relapse of IBD and C. difficile ...................................................................... 23 
6.2.2. Study II: Clinical manifestations of Blastocystis sp. infection .................................... 24 
6.2.3. Study III: Efficacy of influenza vaccination ................................................................ 25 
6.2.4. Study IV: Bolus administration of steroid therapy ...................................................... 28 
6.2.5. Study V: Side effects of cyclosporine A therapy ......................................................... 30 
7. RESULTS............................................................................................................................... 33 
7.1. Study I: Relapse of IBD and C. difficile ......................................................................... 33 
7.2.1. Infection rates and patient follow-up ........................................................................... 33 
7.2.2. Laboratory Findings ..................................................................................................... 34 
3 
 
 
7.2.3. Fecal calprotectin and matrix-metalloproteinase-9 levels ............................................ 35 
7.2. Study II: Clinical manifestations of Blastocystis sp. infection ....................................... 35 
7.2.1.Frequency of Blastocystis spp. ...................................................................................... 35 
7.2.2. Results of stool microbiological examination .............................................................. 36 
7.2.3. Blastocystis sp. and skin manifestations ...................................................................... 37 
7.3. Study III: Efficacy of influenza vaccination ................................................................... 39 
7.3.1. Patient characteristics ................................................................................................... 39 
7.3.2. Antibody titers for Influenza A and B subtypes ........................................................... 40 
7.3.4. Effect of vaccination on IBD activity .......................................................................... 40 
7.3.5. Side effects and development of influenza-like symptoms .......................................... 40 
7.4. Study IV: Bolus administration of steroid therapy ......................................................... 42 
7.4.1. Patient characteristics, clinical response ...................................................................... 42 
7.4.2. Changes in adrenal glands hormone secretion, in the lipid and bone metabolism after 
methylprednisolone therapy ................................................................................................... 43 
7.4.3. Steroid-related side effects ........................................................................................... 44 
7.5. Study V: Side effects of cyclosporine A therapy ............................................................ 45 
8. DISCUSSION ........................................................................................................................ 50 
9. CONCLUSIONS AND NEW RESULTS ESTABLISHED IN THE STUDIES RELATED 
TO THE THESIS .......................................................................................................................... 61 
10. ACKNOWLEDGEMENTS ............................................................................................... 63 
11. REFERENCES ................................................................................................................... 64 
12. ADNEXES ......................................................................................................................... 80 
 
 
 
 
 
 
 
 
4 
 
 
1. ABBREVIATIONS 
 
 
ApoA1: apolipoprotein A1 
BMD: bone mineral density 
BMI: body mass index 
cAMP: Cyclic adenosine monophosphate 
CD: Crohn‟s disease  
CD40: cluster of differentiation  
CDAI: Crohn‟s Disease Activity Index 
CDP: Clostridium difficile positivity 
CMV: cytomegalo virus 
CRP: C-reactive protein 
CyA: cyclosporine A 
DHEA : dehydroepiandrosterone 
DXA: Dual-energy X-ray absorptiometry 
EIM : extraintestinal manifestations 
ELISA: enzyme-linked immunosorbent 
assay 
ESR: erythrocyte sedimentation rate 
FC: faecal calprotectin 
HDL: high-density lipoprotein 
IBD: inflammatory bowel diseases  
IBS: irritable bowel syndrome 
LDL: low-density lipoprotein 
LFA: lateral flow assay 
MMP-9: matrix metalloproteinase-9 
pMayo score: partial Mayo Score 
PTH: parathyroid hormone 
TNF-α : tumor necrosis factor  
TSH: thyroid stimulating hormone 
UC: ulcerative colitis 
VZV: varicella zoster virus 
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4. SUMMARY 
 
 
Introduction. Inflammatory bowel diseases are chronic, multifactorial conditions characterised 
by immune-mediated inflammation of the gastrointestinal tract. Management of IBD represents a 
lifelong medical care as the disorder itself is chronic and permanent with periods of relapses and 
remissions.   However, adverse events can modify conventional treatment of IBD. The aim of the 
thesis was to assess special situations in IBD as infections and side effects: (i) to assess 
Clostridium difficile infection among our outpatients with IBD in relapse, (ii) to assess 
Blastocystis sp. infection and skin manifestations connected it, (iii) to assess efficacy and safety 
of influenza vaccination, (iv) to compare bolus or conventional tapering of methylprednisolone 
for 12 weeks , and (v) to assess serum cholesterol, triglyceride and creatinine levels before, 
during, and after CyA therapy. Patients and Methods. We carried out 5 clinical studies 
connected to the topic. In the Study I, 90 outpatients with IBD who relapse were enrolled 
prospectively. Clinical data of patients were assessed, and stool cultures; in addition, blood and 
stool samples were obtained for the determination of serum biochemical factors, FC and faecal 
MMP-9. IBD patients in clinical remission were selected as a control group. In second study data 
of 80 patients with confirmed positive Blastocystis sp. infections were assessed retrospectively. 
Gastrointestinal and dermatological symptoms and the results of routine biochemical and 
haematological blood tests of enrolled patients were collected and analysed. In Study III, 156 
immunocompromised IBD patients were vaccinated. 53 patients (control group) refused 
vaccination. Split virion vaccine and whole virion vaccine were used. Serum samples were 
obtained for pre- and postimmunisation antibody titres to influenza vaccine (A/California/7/2009 
[H1N1], A/Victoria/361/2011 [H3N2], B/Wisconsin/1/2010–like B/Hubei-Wujiagang/158/2009). 
In Study IV, 19 IBD patients received intravenous methylprednisolone of 1 mg/kg for 5 days 
tapered by 4 mg per week. Patients were prospectively randomized in two groups. In 
“conventional” group (I) steroids were given daily. In “pulse” group (II) weekly dose of steroids 
were given on special days of the week. The BMI was measured before and after the 
corticosteroid therapy. Blood samples were collected to assess glucose level, electrolytes, 
cholesterol and triglycerides levels, inflammatory parameters, cortisol, osteocalcin and crosslaps 
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values. Total body composition analysis was performed at the beginning and at the end of the 
steroid therapy. In the last study, clinical data and serum cholesterol, triglyceride, creatinine 
levels of 72 patients were analysed and compared to a control group treated with infliximab. 
Results. We found that 56.6% of patients had positive microbiological results. Clostridium 
difficile A and B Toxins were verified as positive in 92.1% of these cases. Statistical analysis 
showed a significant difference between FC and MMP-9 values in patients in relapse and 
remission, but not in Clostridium difficile positive and negative cases. Our results revealed an 
association between previous antibiotic use and Clostridium difficile positivity. We discovered 
that 11.25% of our enrolled patients exhibited skin manifestations associated to Blastocystis sp., 
mainly on the females. The occurrence of Blastocystis sp. was 6% in symptomatic patients who 
required medical attendance in the time period between 2005 and 2013. In third study, 
postimmunisation titres of both influenza subtypes increased significantly after the administration 
of split virion vaccines compared to the controls and to those who received whole virion vaccine. 
The antibody titres of Influenza B also increased significantly in patients immunised with split 
vaccine and treated with anti TNF-α therapy. No serious side effects developed occurred after 
influenza vaccination, and the influenza-like symptoms did not differ significantly between 
vaccinated vs. control patients. The relapse of the disease was observed in only 10% of the 
patients, and was more common in vaccinated than in control subjects. In study IV, in Group I, 
BMI increased, total body bone density decreased significantly at the end of the steroid therapy. 
Body fat percent showed a tendency to be higher at the end of steroid therapy in Group I. 
Cholesterol level increased significantly in Group I patients. The decrease in serum cortisol level 
was more remarkable in Group I vs. Group II after steroid therapy. Less side-effect occurred in 
Group II vs. Group I. Lastly, in Study V elevated cholesterol levels were detected in 47.2% of the 
patients. Serum cholesterol levels were significantly increased during and after discontinuation of 
cyclosporine therapy compared to the time before use of the drug. However, cholesterol levels 
measured during cyclosporine therapy were significantly higher compared to the time after its 
discontinuation (p<0.001). Patients with drug-related side effects showed higher cholesterol 
levels after discontinuation of the therapy compared to those who did not experience any adverse 
events. Conclusions. The occurrences of C.difficile and Candida positivity were excessively high 
in patients in an acute relapse, which suggests the importance of intestinal microbiota in IBD and 
an important role in the relapse. FC and MMP-9 has no diagnostic value to differentiate between 
infection-induced and natural relapse. In addition, 11.25% of our enrolled patients exhibited skin 
manifestations associated to Blastocystis sp, that can make a differential diagnostic difficulties, 
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therefore stool analysis is recommended in case of cutaneous lesions of unknown origin. Results 
of Study III showed that split virion vaccines seem to be more effective than whole virion 
vaccines. Measuring the antibody responses is worthwhile in patients treated with 
immunosuppressants to determine the efficacy of influenza vaccination. Our results suggest that 
bolus tapering of corticosteroids may have more favourable short term outcome than 
conventional tapering that may revolutionize steroid therapy in IBD. Considering that 
significantly higher post-therapy cholesterol levels were more common in patients who 
developed drug-related complications, routine measurement of serum cholesterol may increase 
the safety of the drug. 
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5. INTRODUCTION AND AIMS 
 
Inflammatory bowel diseases (IBD: Crohn‟s disease – CD – and ulcerative colitis – UC) are 
chronic, multifactorial conditions characterised by immune-mediated inflammation of the 
gastrointestinal tract with highest incidence of CD in North America, whereas top incidence 
of UC is in Europe (1,2). However, the incidence of IBD is increasing worldwide, including 
developing countries also (3). Etiology of IBD is not exactly understood; however, basically, 
it develops due to the combination of genetic and environmental risk factors that contributes 
to an individual‟s disease susceptibility. Previously in epidemiological and etiological studies 
already had many interest on genetics and environmental factors as racial/ethnic differences, 
smoking, western life-style or urbanization, other socioeconomic factors, dietary influence, 
geographical variations, perinatal factors, vaccinations and appendectomy (4,5,6). IBD may 
occur from early childhood to late adulthood, although more than three quarters of cases are 
currently diagnosed in the twenty-thirty years age population (2). Abdominal pain or cramp, 
diarrhea and rectal bleeding are the main complaints that permanently alter patients‟ quality of 
life. IBD may show many variations of symptoms, disease distribution and degree of activity 
at the onset. Continuous mucosal inflammation of the colon without granulomas on biopsy, 
affecting the rectum and a variable extent of the colon in continuity are presented in UC (7); 
worthy to note that incidence of pancolitis is increasing in adults as well as in children and 
this extension commonly related to severe disease course (8,9). Definition as well as diagnosis 
of CD depends on the finding of discontinuous and granulomatosus intestinal inflammation 
affecting any segment of gastrointestinal tract from mouth to anus. CD has been categorized 
by disease behavior as “non-stricturing, non-penetrating”, „stricturing” and „penetrating” 
according to on presence or abcence of fistulas, abscess and strictures (10). Latella et al. 
defined (11) the crucial steps in the natural history of IBD as the occurrence of lesions, the 
manifestation and severity of symptoms, the need for surgery, the development of 
complications,  disability and mortality; moreover, the main outcomes considered include 
disease activity and relapse, mucosal healing, need for corticosteroid therapy, hospitalizations, 
complications, surgery, post-operative recurrence, and mortality. In spite of the most of 
patients are able to live a normal, productive life, the health care and hospitalizations means a 
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life-long burden, moreover risk of disability pension is probably higher in young IBD patients 
as a recent prospective study showed (12). Degree of disability and/or productivity loss 
depends on general disability from disease activity or localized organic complications, 
treatment-related side effects, and problems related to surgery and hospitalizations (12, 13). 
5.1.  Keypoints in the management of IBD – infections and side effects  
Management of IBD represents a lifelong medical care as the disorder itself is chronic and 
permanent with periods of relapses and remissions (14).   However, some special situations 
modify conventional treatment of IBD like adverse events, infections, pregnancy, grown 
problems in childhood, nutritional difficulties, and malignancies (15,16). 
Just as with the initial manifestation of IBD, the factors which cause subsequent relapses are 
also ambiguous in most cases; however, an infective agent may play a role in both the 
manifestation and the relapse (17). Risk of infections is increased evidently due to underlying 
disease and other comorbidities, malnutrition, surgical procedures and immunosuppressive 
therapy (18,19,20,21,22). Clostridium difficile is a pathogen which came to the front of 
interest due to high prevalence among IBD patients, and associated with increased mortality.  
Studies (23) had reported about altered intestinal microflora in IBD, in this manner consider 
to pay attention of avoidance of dysbiosis and microorganisms like C.difficile and Candida 
species that leads even a serious symptom and inflammation in special circumstances, thus 
had influence on optimization of therapy (Study I).  
Microbes have significant concern to differential diagnosis also, because some of them may 
provoke gut and extraintestinal symptoms similar to IBD. Immune-mediated inflammation in 
IBD leads to gastrointestinal symptoms primarily, although extraintestinal manifestations 
(EIM) may develop also. Varying symptoms of EIMs appear in 15-20% of UC patients and 
20-40% of CD patients; despite of frequently occurrence, the therapy is often empirical (24, 
25). The most common extraintestinal manifestations or extraintestinal complications beyond 
the IBD include arthropathies, mucocutaneous and ophthalmological manifestations, as well 
as conditions affecting the hepatobiliary system. Less frequent manifestations are pulmonary 
and neurological symptoms, but these disorders should be considered also as EIMs of IBD 
(26). Skin is the most common affected extraintestinal organ with varying cutaneous 
symptoms. Typical skin manifestations are the specific perianal or metastatic CD lesions, the 
reactive pyoderma gangrenosum, the IBD-associated erythema nodosum. Occurrence of the 
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drug-induced cutaneous manifestations as psoriasis-like, eczema-like lesions is progressive 
increasing. (27). EIMs may appear parallel with first signs of IBD, but any time during 
disease course. However, other intestinal disorders like Blastocystis sp. infection may 
associate with EIMs also that make a meaningful difficulty in differential diagnosis of IBD 
(28,29,30) (Study II).  
Regards to infections, prevention is significantly important step of patient management 
including the recognition of risk factors for infection, the use of primary or secondary 
chemoprophylaxis, careful monitoring before and during use of immunomodulators and the 
vaccination and education of the patient (31). Patients with IBD on immunosuppressive 
therapy are at increased risk for infective diseases, some of which can be prevented by 
immunization.  According to present standpoint, immunisation status should be control at the 
diagnosis, and vaccination should be performed before initiation of immunosuppressant 
therapy. In addition, VZV varicella (if there is no history of chickenpox, shingles, or VZV 
vaccination and VZV serology is negative), human papilloma virus, influenza (once a year), 
pneumococcal polysaccharide, hepatitis B (HBV seronegative cases) vaccines should be 
considered at the diagnosis (20). Respiratory infections are the most frequently reported 
complications in this population (32). Influenza infection is frequent and may have severe 
complications, however, it is a preventable modality, and thus vaccination is recommended 
(Study III). On the other hand, vaccination rates are relatively poor reflecting the low 
willingness of patients and medical doctors also. Numerous patients do not accept vaccination 
because of fear of side effects, and many doctors do not propose vaccine against influenza 
virus due to uncertain response to immunisation.  
As it mentioned, immunosuppression can be the consequence of immunomodulatory therapy. 
Not just a risk of subsequent infection could occur in patients on immunosuppressants, but 
their use can result other side effects also. Pharmacological treatment of IBD includes the 
aminosalycilates (sulphasalazine, mesalazine), the corticosteroids, the immunosuppressants 
such as the thiopurine analogs (6-mercaptopurine and its pro-drug azathioprine), 
methotrexate, and the calcineurin inhibitors (cyclosporin and more recently tacrolimus), in 
addition the biological therapy (principally infliximab, adalimumab) depending on disease 
involvement and severity (33,34). Algorithms of medical management of CD and UC differ 
according to course and behaviour of diseases; however the goal of both therapies is reach and 
maintains the clinical and endoscopic remission (35,36). Corticosteroids still have an 
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important role in the management of acute episodes of IBD. Parenteral corticosteroids are 
usually the first treatment of choice for hospitalized patients with severe UC and CD (37). 
However, the therapeutic benefits are compromised by an extensive spectrum of adverse 
events; although in a recent years therapy strategies aimed to minimalize the side effects by 
careful drug administration and patient monitoring and using topically acting oral steroids (eg. 
budesonid) characterized by low systemic bioavailability (38). However, in case of moderate 
to severe disease activity use of classical systemic corticosteroids seems to be irreplaceable by 
new formulas, in this reason worth to study the response to different steroid administration 
types and their side effect profile. (Study IV) 
Unfortunately, one third of UC patients is corticosteroid refractory, thus for them 
cyclosporine A, biological therapy or proctocolectomy is recommended in severe relapse (35). 
Adverse events of cyclosporine A that range from mild to severe, may lead even to 
discontinuation of the drug (Study V). Beyond treatment of acute relapses, patients should be 
monitored due to control short- and long-term effects of therapy. 
 
5.2.  Study I.: Role of the microorganism in the etiology and relapse of IBD 
The triggering role of Clostridium difficile infection in the relapse of IBD and the clinical 
utility of faecal markers in the diagnosis of relapses with a different aetiology. 
Outstanding concepts of etiology of IBD are the immune reaction to a persistent intestinal 
infection, existence of a defective mucosal barrier to luminal antigens and a dysregulated host 
immune response to ubiquitous antigens (39). Some animal experiments suggest a role played 
by bacteria in the pathogenesis of IBD: interleukin-10 knockout, germ-free mice do not 
develop colitis; however, interleukin-2-deficient mice develop spontaneous colitis after 
Escherichia coli exposure, but not with Bacteroides vulgatus exposure (40). Thus, compound 
of gut microflora has a significant importance. Intestinal microbiome consists of overall 100 
trillion diverse microbes, including over 1100 prevalent species, but in each subject with at 
least 160 species (41). Studies on the intestinal microbiota has been progressed rapidly: 
investigations from one species (for example Faecalibacterium prausnitzii, Escherichia coli) 
(42, 43, 44) towards to diversity and interactions (45, 46, 47). Dysbiosis is a definitive change 
of the normal gut microflora with a disintegration of host-microbial mutualism. Qualitative 
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and quantitative changes in intestinal microbiome have been reported in patients with IBD. 
Reduced number of the phylia Firmicutes, particularly Faecalibacterium prauznitzii, and in 
opposite, inceased amount of the phylium Bacteroides have been noted in subjects with IBD 
(48). Proteobacteria phylium have been described to have a key role in IBD as an aggressor 
factor in initiation of chronic inflammation (49,50). Importance of dysbiosis in IBD is 
obvious, but more important question is whether how responds the host to dysbiosis and 
whether which was first the discrepant immune response or the dysbiosis? Interactions of 
human gut microbiome and host/intestinal mucosa have basic importance, nevertheless many 
associations exist with life-style and environmental factors that interfere with (51, 52).   
Although the aetiology of IBD has not been unequivocally clarified, an altered intestinal 
immune response due to the interaction of several environmental and genetic factors is 
observable, which may lead to inadequate gut flora compound and function, thus making the 
intestine vulnerable to superinfections like the Clostridium difficile (C.difficile) infection 
(53,54,55). C. difficile came to the front since epidemiological data showed high prevalence 
of this bacterium (56,57) among IBD patients. Current data suggest that in patients with CD 
or UC, infection of this anaerobic bacterium occurs more frequently than in the general 
population (58,59,60). The significance of CDP (C.difficile positivity) manifests not only in 
its increasing incidence, growing antibiotic resistance and severe disease course, but also in 
the magnitude of the infections, which also leads to high health care costs. Expansion of CDP 
is more pronounced in IBD patients; moreover, its prevalence has been reported in 5 to 19% 
in patients with active disease (61,62). However, data from available prospective studies are 
limited. 
The usual diagnostic check-up in case of a flare-up consists of faecal microbiological 
examination and an evaluation of inflammatory biochemical and stool biomarkers. None of 
these tests can immediately differentiate between infection-caused and natural relapse, and 
considering that most of the outpatients came from a long distance, microbiological validation 
of the stool sample is often delayed at the expense of treatment. On the other hand, in 
Hungary, C. difficile bacterium and toxin testing is not ordinary in every hospital, usually only 
clinical centres perform routine C.difficile testing procedures. A simply and quickly 
performing marker would be useful as strong point in the differentiation of an infective origin 
or exacerbation. Faecal calprotectin (FC) and matrixmetalloproteinase-9 (MMP-9) are 
markers that correlate with disease activity, but they cannot give a reliable differentiation in 
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the case of specific IBD. FC is a neutrophil leukocyte-derivate protein eligible for 
distinguishing IBD from functional disorders (63). In vitro resistance to degradation allows 
faecal samples to be assayed for reliable calprotectin determination. FC has a high sensitivity 
in the determination of IBD activity; however, elevated levels were also shown in intestinal 
infections, tumours and colon polyps, therefore its specificity is less favourable. MMP-9 is a 
Zn-binding neutral proteinase produced by polymorphonuclear cells. MMP-9 is one of the 
major contributors to the breakdown and reconstruction of the extracellular matrix (64). 
Faecal MMP-9 in UC patients is an excellent marker of disease activity and shows significant 
correlation with clinical and endoscopic scores (65). 
 
5.3.  Study II: Role of microorganism in the development of cutaneous lesions: a 
specific extraintestinal manifestation associated with an  infective intestinal 
disorders  
Don’t Forget the Stool Examination! – Cutaneous and Gastrointestinal Manifestations of 
Blastocystis sp. Infection.  
Out of IBD, gluten-sensitive enteropathy, polyposis syndromes and gastrointestinal 
malignancies are bowel diseases which are often accompanied by special extraintestinal 
cutaneous manifestations (66). Typical clinical scenario is a combination of non-specific 
gastrointestinal symptoms and recurrent non-specific skin abnormalities that cause the most 
commonly food allergy or small intestinal bacterial overgrowth. Testing for infective agents 
as Helicobacter pylori infection is also a common practice, although a microbiological stool 
examination should be one of the first diagnostic procedures in these cases. One of intestinal 
infections that provoke EIMs, first of all skin manifestations beside gastrointestinal symptoms 
is Blastocystis spp. infection (67). Blastocystis sp. is a protozoan genus with mitochondria-
like organelles and at least one nucleus. It is an anaerobic microorganism; therefore, the 
mitochondria-like organelles presumably do not function in oxidative phosphorylation (68). 
This unicellular, obligate anaerobic protozoon, which resides mostly in the colon and the 
caecum, is one of the most common parasites in the human intestinal tract, and colonization 
has also been observed in many vertebrates. Incidence of Blastocystis sp. is varying 
worldwide. In healthy adults the prevalence has been reported to be between 30 and 50% in 
developing countries and between 1.5 and 10% in developed countries (69). Blastocystis sp. 
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infection commonly causes diarrhoea and abdominal pain, but extraintestinal symptoms, such 
as skin lesions, may also accompany this condition (70). On the other hand, it is not 
absolutely clear whether Blastocystis sp. is a commensal microorganism, harmless and only a 
cause of infection under special circumstances, or a true pathogen (71,72). Several studies 
reported skin manifestations, particularly urticaria, connected to this protozoon (73,74). 
Blastocystis sp. and Giardia intestinalis (75) are supposed to be the two most culpable 
protozoa on the basis of studies of the parasitological aetiology of urticaria. Urticaria may 
occur both IBD-associated cutaneous disorder and as skin side-effect of drugs used in the 
treatment of IBD (aminosalicylates, metronidazole, ciprofloxacin, azathioprine) (76).Thus, 
both IBD and Blastocystis sp. associated urticaria may occur presenting a differential 
diagnostic problem. 
 
5.4.  Study III: Efficacy and safety of immunisation in  immunocompromised IBD 
patients 
Antibody and Cell-mediated Immune Response to Whole Virion and Split Virion Influenza 
Vaccine in Patients with Inflammatory Bowel Disease on Maintenance Immunosuppressive 
and Biological Therapy.  
Influenza is one of the most common vaccine-preventable illness in adults and according to 
the latest statement of the European Crohn‟s Colitis Organization (20) on the prevention of 
opportunistic infections in IBD, and influenza vaccination is recommended for all patients 
with IBD on immunomodulators. Although several guidelines exist for the vaccination of 
patients with IBD, it still seems to be underused and the results of the studies on the immune 
response after vaccination are also conflicting (77).  
One of the studies conducted in paediatric IBD patients (78) revealed that children receiving 
both infliximab and immunomodulators had a lower response to 2 influenza vaccine antigens 
(A/New Caledonia/20/99 and B/Hong Kong/330/2001) when compared with healthy controls. 
The prospective study of Lu et al. revealed a high prevalence of seroprotection in children and 
young adults with IBD, particularly against A strains (79). They did not detect difference 
among non-immunosuppressed and immunosuppressed patients. However, in adults, the types 
of immunosuppressive and biological therapies seem to influence the immune response to 
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vaccinations (80). Additionally, the majority of the studies aims to examine only the rate of 
seroprotection and does not consider the importance of the frequency of infections in 
vaccinated vs. not vaccinated patients. 
Although vaccination against influenza is recommended, more and more information is 
needed in special clinical situations to make a proper decision according to adequate patient-
and vaccine type selection. 
 
5.5.  Study IV: How to decease steroid side effects? 
Bolus Administration of Steroid Therapy is More Favorable than the Conventional Use in 
Preventing Decrease of Bone Density and the Increase of Body Fat Percentage in Patients 
with Inflammatory Bowel Disease.  
Use of steroids is associated with some well-known potential harmful side-effects; therefore 
oral steroids are recommended to be gradually tapered off and discontinued after 12 weeks in 
case of appropriate response to the parenteral therapy. Corticosteroid therapy is known to 
contribute to changes in body composition with the alteration of protein synthesis and 
degradation in skeletal muscle, resulting in decreased muscle mass and reduced fat-free mass. 
Steroids also lead to a reduction in the total body bone mineral density (BMD) (81). Therefore 
total body composition analysis is a useful method for quantification of multiple whole body 
and regional components, including bone mineral, fat, and lean soft tissue in patients treated 
with steroids. It gives a direct measurement of the percent body fat, muscle and bone (in 
grams) for the entire body and sub regions like the arm, leg, and trunk. 
The optimal dose response for parenteral steroids in the treatment of severe attacks has not 
been clarified yet; dosages of methylprednisolone 40-60 mg or 1 mg/kg per day orally are the 
most frequently used regimen (37, 82) for flare up. Furthermore, no randomized trials have 
studied and even no guidelines have been developed by the European Crohn‟s and Colitis 
Organisation on taper schedules. After the induction of remission, methylprednisolone is 
usually tapered 8-16 mg weekly until a daily dose of 32 mg is reached followed by a tapering 
of 4 mg/wk. Tapering steroid regimen is most frequently carried out by administrating the drug 
daily, although alternate-day steroid management (given every other day) has also been a 
widely employed and effective mode of therapy for ages associating with fewer unpleasant side 
effects (83). The efficacy of “bolus-administered” corticosteroids when weekly dose of steroid 
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regimen is given on special days has not been previously examined in patients with IBD. The 
effect of a “short-term” 12-week course of corticosteroids on the metabolic processes and bone 
formation has not been well studied too; although these are some of the most important side 
effects should be considered.  
 
5.6.  Study V: An underdiagnosed common side effects of calcineurin inhibitor 
therapy 
Long-term Increase in Serum Cholesterol Levels in Ulcerative Colitis Patients Treated with 
Cyclosporine: an Underdiagnosed Side Effect Frequently Associated with Other Drug-related 
Complications.  
Flare-ups of UC can be very severe, requiring hospitalisation, and they can have life-
threatening complications, such as toxic megacolon, perforation and severe bleeding in 15% 
of the cases (84). One third of the patients seem to be refractory to steroid therapy, but in 
these severe clinical situations possible alternatives to total proctocolectomy are cyclosporine 
A (CyA) and infliximab (13). Meta-analyses of the relatively limited amount of published 
data available have revealed a similar effectiveness profile for CyA and infliximab therapies 
(85), although the lower cost of CyA is undeniable (86). Cyclosporine A is a type of 
calcineurine-inhibitor which binds to immunophilins protein localized intracellularly. That 
complex attaches to calcineurin, thus inhibit its activation, and hence inhibiting T cell 
activation. Blocking transcription and expression of some cytokines (interleukin-2: IL-2, 
interleukin-4: IL-4, cluster of differentiation 40: CD40) and co-stimulatory molecules, T cell 
growth and differentiation interfere also (87). Since the short-term bowel-saving capacity of 
CyA is excellent, the remaining major issues are presented by long-term outcomes and the 
safety of CyA (88). Recently published studies have proven that the longer duration of CyA 
therapy and the concomitant use of azathioprine are associated with a significantly lower 
colectomy rate than expected, although the development of side effects still remains a 
problem (88,89).  
The most well-known major adverse effects of CyA are nephrotoxicity and hepatotoxicity. 
The incidence of minor adverse reactions such as tremor, paraesthesia, malaise, headache, 
gingival hypertrophy and hypertrichosis varies between 31% and 51% (89). The manifestation 
of these side effects may lead to the discontinuation of the CyA therapy in a significant 
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proportion of patients, although the majority of the patients under regular monitoring of CyA 
blood levels are able to continue the therapy for more than one year for cases of psoriasis 
(90). An increase in cholesterol levels is a known side effect of CyA in transplant patients; 
however, we have limited data about the long-term influence on lipid metabolism in UC. 
Ballantyne et al. (91) measured lipoprotein levels in cyclosporine-treated patients undergoing 
heart or kidney transplantation. Significant increases in total (21%) and low-density 
lipoprotein cholesterol (31%) occurred only in the cyclosporine group of patients. 
Cyclosporine therapy by itself was found to affect plasma lipoprotein levels adversely by 
increasing total cholesterol levels.  
5.7. Aims 
1. To prospectively assess the frequency of C.difficile among our outpatients with IBD in 
relapse; in addition, to estimate the conduciveness of clinical and differential diagnoses of FC 
and MMP-9 in cases of both infection and non-infection. 
2. To retrospectively assess the attributes of patients with a confirmed positive Blastocystis sp. 
infection who came to our clinics at the University of Szeged between 2005 and 2013, 
primarily to examine the occurrence of clinical gastrointestinal symptoms and skin 
manifestations. 
3. To assess the antibody response to the seasonal influenza vaccine in patients with IBD 
treated with anti-TNF-α alone or combined with immunosuppressive therapy and to compare 
them with patients receiving non-immunosuppressive therapy. The secondary goal in this 
study was to compare the antibody response and the safety of whole virion and split influenza 
vaccines. The last aim was to evaluate the effects of the vaccines on IBD clinical activity. 
Last, but not least this study was also aimed to evaluate the acceptance of the vaccination in 
our patients and to assess the frequency of influenza infection in vaccinated vs. non 
vaccinated patients. 
4. To compare the efficacy, the frequency of side effects and the changes in bone and lipid 
metabolism in IBD patients using bolus or conventional tapering of methylprednisolone for 
12 weeks. 
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5. To prospectively assess serum cholesterol, triglyceride and creatinine levels before, during, 
and after CyA therapy in patients with severe, refractory UC and to examine the correlation 
between plasma lipoprotein levels and other side effects. 
 
6. PATIENTS AND METHODS 
6.1.  Description of methods  
6.1.1. Enzyme-linked immunosorbent assay 
The basic immunology concept of enzyme-linked immunosorbent assay (ELISA) technique is 
a specific antigen- antibody binding. ELISA operates with enzyme-labelled antigens and 
antibodies to detect the biological molecules. Presence of antigen is indicated when 
chromogenic substrate for the enzyme yields make a visible colour change (92). 
Fecal MMP-9 concentrations were measured using ELISA method (Quantikine MMP9 assay, 
R&D System, UK) in our clinical study. One gram of the sample was diluted and 
homogenised in 4 ml of an ice-cold buffer (0.15M NaCl + 20mM Tris-HCl, pH:8.3). The 
suspension was then centrifuged at 1500g for 10 min and the supernatant was recentrifuged at 
10,000g for 10 min. The final supernatant was filtered and stored at -20˚C until analysed. 
Determination was in accordance of manufacturer‟s instructions. 
From the collected sera samples, anti-influenza A virus IgG ELISA( Euroimmun, Germany) 
containing the following antigens “Texas” (H3N2), “Singapore” (H1N1) and “California” 
(H1N1) strains of influenza A virus was performed according to the manufacturer‟s 
recommendation. The results were evaluated quantitatively using calibration curve. From the 
above-mentioned sera specimens, anti-influenza B virus IgG ELISA (Euroimmun, Germany) 
was also set up. In this case, the antigen source was “Hongkong 5/72” strain of Influenza B 
virus. The results were also interpreted quantitatively.  
6.1.2. Lateral flow assay 
Fundamental mechanism of lateral flow assay (LFA) is the movement of fluid sample or its 
extract, along a strip of polymeric material though various zones where molecules are 
attached with more or less specific interacting with the analyte. Usage of labels made of 
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coloured or fluorescent nanoparticles are allowing the visualisation, and quantitation of 
response (93). 
FC levels were measured by a quantitative LFA (Quantum Blue, Bühlmann Labortories, 
Switzerland). Samples for FC determination were stored at -20°C until analysed. Faecal 
specimens were thawed and prepared for a calprotectin assay as described by the 
manufacturer.  
6.1.3. Microbiological examination of stool samples 
A microbiological analysis (involving bacteria, fungi and, in reasonable cases, viruses and 
parasite examination) for the presence of an enteric pathogen was carried out at the Institute 
of Clinical Microbiology, Szeged. Laboratorial diagnosis of C. difficile was based on 
microscopic identification of bacterium; the detection of Toxin A and B was completed by 
using the ELISA method. 
The laboratorial diagnosis of Blastocystis sp. colonization was based on directly microscopic 
detection of trophozoites and/or cyst forms. A culture of the organism from the stool was also 
performed in cases of microscopically negative direct smears. It was carried out using Boeck-
Drbohlav-Locke-egg serum medium (94).  
6.1.4 .Statistical analysis 
The collected data were analysed statistically. P<0.05 was considered statistically significant. 
For the analysis, SPSS15.0 (SPSS Inc, Chicago, IL, USA) was used. 
      6.1.5. Ethical Considerations 
The studies were approved by the Regional and Institutional Human Medical Biological 
Research Ethics Committee of the University of Szeged. 
 
6.2. Patients and methods of clinical studies 
Diagnosis was based on the Lennard-Jones Criteria (95), in addition disease phenotype was 
determined according to the Montreal Classification (96). The clinical activity of CD and UC 
were assessed using the Crohn‟s Disease Activity Index (CDAI) (97) and with a partial Mayo 
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Score (pMayo) (98), respectively. Relapse was defined as ≥150 points with an increase of 
≥80 points in the CDAI in the case of CD and ≥3 points in the pMayo score in the case of 
UC.  
 
6.2.1. Study I: Relapse of IBD and C. difficile 
90 patients with symptoms of a flare-up were enrolled in our study with 49 control subjects in 
clinical remission from September, 2012 to July, 2013. All of them were outpatients at the 
First Department of Medicine, Szeged. The medical data of patients were collected 
prospectively. Clinical data, activity indexes, faecal specimens and serum samples were 
analysed of IBD patients who manifested worsening symptoms –indicating a potential flare-
up – and of patients in remission. Blood samples were taken from all patients for the 
determination of CRP levels (C-reactive protein), platelet and leukocyte count, serum iron 
level and haemoglobin level. Faecal samples from every subject were sent to the 
microbiological laboratory of the Institute of Clinical Microbiology. The clinical 
characteristics of the patients are presented in Table 1. The activity of IBD and the presence 
of an enteric pathogen were carefully assessed at each visit, and laboratory findings were 
entered into the clinical records.  
The collected data was analysed statistically, using Pearson‟s chi-square test, Pearson‟s chi-
square test with Yates‟ continuity correction and Wilcoxon rank sum test with continuity 
correction. 
Table 1. Clinical characteristics of patients. 
 Relapsing group (n=90) Control group (n=49) 
Gender (male/female) 44/46 28/21 
Age (years) 36.7 (16 to 79) 38.7 (19 to 75) 
UC/CD 51/38 25/24 
Disease duration (years) 6.9 (0 to 26) 10.2 (0 to 46) 
Appendectomy (%) 10.8 3.8 
Smoking (%) 37.7 16.1 
Perianal involvement 
(%) 
16.8 10.9 
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Extraintestinal 
manifestation (%) 
42.7 22.9 
Immunosuppression 
(%) 
48.8 53 
Gastricacid-
suppressant agent (%) 
27.7 16.6 
Previous antibiotic use 
(%) 
20 20.4 
CDAI  227.9 (140 to 450) 71.04 (-5 to 127) 
pMayo Score 5.2 (3 to 9) 0.56 (0 to 2) 
FC (μg/g) 1292.5 (29 to 6800) 216.1 (29 to 1370) 
Fecal MMP-9 (ng/mL) 11.8 (0 to 168.8) 3.5 (0 to 22.2) 
CRP (mg/L) 23.5 (1 to 202.6) 6.5 (1 to 40.8) 
Leucocytes (G/L) 10.05 (3.9 to 90.6) 7.06 (3.6 to 14.7) 
Thrombocytes (G/L) 333.7 (169 to 657) 283.4 (88 to 602) 
Serum iron (μmol/L) 11.2(1.9 to 25.3) 15.04 (4.4 to 33.1) 
Hematocrit (%) 39 (21 to 49) 40 (33 to 47) 
 
6.2.2. Study II: Clinical manifestations of Blastocystis sp. infection 
The first part of our study determined the frequency of occurrence of a positive Blastocystis 
sp. infection among patients treated at the University of Szeged clinics between 2005 and 
2013. A routine microscopic parasitological examination was performed on stool samples 
from 3255 patients, based on the patients‟ symptoms and complaints. Physicians requested 
stool examinations based on their assessment of the patients‟ clinical characteristics. 
We subsequently assessed the frequency of Blastocystis sp. in 1471 patients at the First 
Department of Medicine with adult gastroenterology profiles who needed a stool protozoon 
examination between January 2005 and May 2013. In addition, data of 80 patients at the First 
Department of Medicine with confirmed positive Blastocystis sp. infections were assessed 
retrospectively (Table 2). Every patient of our cohort complained about different 
gastrointestinal symptoms, such as diarrhoea, abdominal pain, bloody stool, and meteorism. 
The results of routine biochemical and haematological blood tests of positive cases, as well as 
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the results of any relevant examinations performed during dermatological evaluations, were 
collected from the clinical database.  
Table 2. Clinical data of Blastocystis sp. positive patients. 
Number of patients 80 
Gender (Male/female) 32/48 
Age at Blastocystis sp. infection (years) 13-85 (Mean: 46.3) 
 
The most frequent symptoms in enrolled patients: Number of cases: 
Abdominal pain  40 
Blood in stool  17 
Meteorism  15 
Weight loss  8 
Perianal symptoms  6 
Mucus in stool  5 
Vomitus  2 
Fever  2 
Skin manifestations 9 
 
Symptoms, laboratory findings (elevated CRP, increased number of eosinophils, leucocytes 
and lymphocytes, etc.) and accompanying chronic diseases (lactose intolerance, IBD, 
gastroesophageal reflux disease, etc.) were statistically compared between patients with vs. 
without skin manifestations. Categorical data was analysed using Fischer‟s exact test, or one-
sided Fischer‟s exact test. Continuous data was analysed using Student‟s t-test and Mann-
Whitney U-test. 
6.2.3. Study III: Efficacy of influenza vaccination 
    We conducted a multicentre, prospective cohort study from September 2012 through May 
2013 in 4 Hungarian IBD centres (2
nd
 Department of Medicine, Semmelweis University;
 
1
st
 
Department of Medicine, Semmelweis University;
 
Military Hospital, Budapest; Integrated 
Szent Istvan and Szent László Hospital, Budapest). Patients with active IBD were excluded. 
At inclusion, influenza vaccination was offered to every patient attending the involved centres.  
Patients were randomized to two groups on the basis of the acceptance of the vaccination. 
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Patients refusing the vaccination served as control subjects. Patients and control subjects were 
followed up to 4 months to determine the clinical activity and the frequency of influenza 
infections. Clinical data and immunisation history in the previous 5 years was also obtained. 
Patients who received vaccination were divided into two further groups: patients treated with 
aminosalycilates without immunosuppressive therapy and patients treated with 
immunomodulator and/or biological therapy for at least three month at the vaccination. 
Control subjects have received maintenance therapy with immunomodulator and/or biological 
therapy for at least three month at the vaccination. 
The type of vaccine (whole virion or split virion vaccine) was randomly selected. The patients 
were scored and blood samples were also taken before and after the vaccination. Serum was 
collected at baseline (pre-vaccination) and 5-6 weeks after vaccination and it was stored at -
20 
o
C until used. We compared the antibody titers of influenza A and B subtypes between 
vaccinated and control patients; between vaccinated patients receiving immunosuppressive 
(thiopurine, biological therapy) and non-immunosuppressive therapy (aminosalycilates); 
between vaccinated and control patients receiving immunosuppressive maintenance therapy 
and between patients vaccinated with whole virion and split vaccine receiving 
immunosuppressive therapy. Demographic and clinical characteristics, disease activities at 
the time of the vaccination and treatment types are summarized in Table 3.  
Two non-live vaccines directed against the seasonal influenza virus A/California/7/2009 
(H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010–like B/Hubei-
Wujiagang/158/2009 were used in the study. Inactivated, split virion vaccine (IDFlu9) and 
inactivated, whole virion vaccine (Fluval AB) were administrated depending on the random 
selection. The experimental use of whole virion vaccine, that is the first of the inactivated 
vaccine formulation, dates back to 1940s. Split virion is derived by disrupting whole virus 
particles with detergents thus being less immunogenic than whole virion vaccines (99). 
Whole virion vaccine was administered intramuscularly; split virion vaccine was 
administered by intradermal route. 
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Table 3. Clinical characteristics of patients. 
 
All patients 
(n=209) 
Fluval AB 
vaccinated (n=57) 
IDFlu9 
vaccinated 
(n=99) 
Controls 
(n=53) 
Male/Female 96/113 30/27 42/57 24/29 
Mean age at diagnosis 
(years) 
28.6 27.2 28.3 30.7 
Median disease duration 
(years) 
9 9 9 7 
CD/UC 127/82 46/11 52/47 29/24 
Disease location 
- L1 
- L2 
- L3 
- L4 
 
25 
46 
54 
2 
 
10 
14 
21 
1 
 
10 
20 
22 
0 
 
5 
12 
11 
1 
Disease behaviour 
- B1 
- B2 
- B3 
 
41 
24 
62 
 
14 
9 
23 
 
19 
12 
21 
 
8 
3 
18 
Extent of UC 
- E1 
- E2 
- E3 
 
21 
28 
33 
 
3 
5 
3 
 
11 
16 
20 
 
7 
7 
10 
Therapy 
- Aminosalycilates 
- Thiopurines 
- Anti TNF-α 
- Combined thiopurines 
and anti TNF-α 
 
21 
27 
26 
62 
 
5 
7 
10 
20 
 
6 
14 
12 
20 
 
10 
6 
4 
22 
Mean CDAI 120.3 108.4 133.2 137.5 
Mean pMayo score 1.8 1.7 1.6 2.1 
 
We assessed cell-mediated immune response after vaccination and also compared in patients 
treated with and without immunosuppressants. The patients were contacted by phone every 
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week throughout 16 weeks. During the phone calls, data from each patient were collected 
using a standardised questionnaire. The patients were interviewed about the change in clinical 
activity and the development of local and systemic adverse reaction.  
Categorical data were analysed using Pearson‟s chi-square test and Fisher‟s exact test. The 
effects of the vaccination on the antibody and cell-mediated immune response were examined 
with multivariate analysis of variance (MANOVA) models with time as repeated measures 
(within-subject) factor and the types of the vaccines, the immunosuppressive status, the 
vaccinated status, the different therapies and the development of side-effects and influenza-
like symptoms as between-subject factors. Pairwise comparisons were performed on 
estimated marginal means by considering the presence or absence of interaction; p-values 
were corrected with the Holm-Sidak method. 
6.2.4. Study IV: Bolus administration of steroid therapy 
This single-center, prospective, randomized trial was carried out from November 2011 to 
February 2013 on consecutive patients with acute exacerbation of IBD and not being on 
steroid therapy admitted to our clinic. Twenty patients were enrolled in the study (Table 4). 
The median CDAI and partial Mayo score were 184 and 6 in CD and UC at the time of the 
enrolment. None of the patients received oral corticosteroid at the time or at least 6 months 
before the enrolment. On admission a complete blood chemistry including erythrocyte 
sedimentation rate (ESR), CRP, serum glucose, electrolytes, liver and renal function, 
cholesterol, triglycerides, blood count, serum cortisol, calcium, dehydroepiandrosterone 
(DHEA), thyroid stimulating hormone (TSH), parathyroid hormone (PTH), ß-crosslaps and 
osteocalcin levels were performed before starting steroid therapy. The mean value of CRP, 
ESR, leukocytes and thrombocytes before steroid therapy were 16 mg/l, 21.5 mm/h, 8.828 G/l 
and 322 G/l. Flexible colonoscopy or sigmoidoscopy with biopsies was carried out only in 
patient with relevance to therapy, however, it was not essential for inclusion into the trial. 
Thus, 3 CD and 13 UC patients underwent colonoscopy at inclusion. DXA total body 
composition analysis was also performed at the beginning of the study to determine the fat and 
fat-free component of the body.  
Patients eligible for iv. steroid therapy received methylprednisolone dosage 1 mg/kg for 5 
days. After iv. therapy, patients were prospectively randomized in two groups. In 
“conventional” group (Group I) methylprednisolone was given daily while in “bolus-
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administered” group (Group II) weekly dose of steroids were given on special days of the 
week. 64 mg/day methylprednisolone dose at the first week in Group I was equal to 150 
mg/day given in the first 3 days in Group II. Finally, both groups received the same 
methylprednisolone dose and it was tapered by 4 mg per week in both groups. The two 
different types of methylprednisolone dosages are detailed in Table 5. Follow up appointments 
were done every two weeks. These visits involved the assessment of the clinical activities by 
the determination of CDAI and pMayo scores. Patients were asked about side effects, the BMI 
was determined and the waist and hip circumferences were also measured. Laboratory 
assessment (including inflammatory parameters, electrolytes, glucose level, liver and renal 
function, and blood count) was carried out every four weeks. Detailed laboratory parameters 
(DHEA, THS, PTH, serum cortisol, serum ß-crosslaps and osteocalcin levels) and DXA for 
total body composition analysis were performed at week 0 and week 12.  
 
Table 4. Clinical characteristics of the enrolled patients 
 
 
 
 
 
 
 
 
 
 
 
  Group I (n=9) Group II (n=10) 
Mean age at the diagnosis (years) 34.3 30.3 
Mean disease duration (years) 5.2 6.2 
CD/UC 3/6 3/7 
Female/male 4/5 2/8 
Location/extension 
- Ileal 
- Colonic 
- Ileocolonic 
- Extensive colitis 
- Left-sided colitis 
- Proctitis 
 
1 
2 
- 
3 
3 
- 
 
2 
1 
- 
5 
2 
- 
Concomitant therapy 
- 5-ASA 
- Budesonide 
- Azathioprine 
- Metronidazole 
 
4 
0 
3 
2 
 
6 
2 
4 
1 
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The Student‟s t-test was employed to compare continuous variables. Multivariate analysis with 
stepwise logistic regression by SPSS software was performed to investigate the parameters 
with a possible influence on clinical outcome, such as age, gender, location of disease, 
duration of disease, concomitant immunosuppressive therapy. The differences between the 
two groups were performed by mixed effects ANOVA model for repeated measures. The 
results were corrected using a Bonferroni-Holm method for multiple testing.  
 
Table 5. Methylprednisolone dosages in the conventional and the bolus administration groups 
 
6.2.5. Study V: Side effects of cyclosporine A therapy 
72 patients suffering from severe, steroid-refractory UC were enrolled in our study from our 
tertiary clinic between January 1998 and June 2009. In the acute phase, intravenous 
cyclosporine was administered at the initial dose of 5 mg/kg for seven days, then, depending 
on serum levels of the drug, the dosage was modified (to 2-4 mg/kg). Subsequently, oral 
treatment was administered at a mean dose of 4.7 mg/kg, adjusted according to serum levels 
of the drug, and co-administration of azathioprine, at a dose of 2 mg/kg, was also started in 
naïve patients. Patient data were collected prospectively. Patient demographic data are 
detailed in Table 6. 
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 Cyclosporine serum levels were regularly monitored during application of the therapy. The 
normal range of fasting levels and of 2-hours-post-dose levels were determined, based on 
transplant data, to be between 100 and 200 μg/L and between 800 and 1,400 μg/L, 
respectively. Our UC patients had received concomitant steroid therapy, but this was tapered 
off within 3 months after starting cyclosporine therapy. 
Total cholesterol, triglyceride and creatinine levels had been collected prospectively before, 
then at the time of and after administration of the cyclosporine therapy. The normal total 
cholesterol level was defined as less than 200 mg/dL, normal triglyceride level as less than 
150 mg/dL and normal serum creatinine in the range of 0.6-1 mg/dL. Cholesterol and 
triglyceride levels were measured at months 3, 6 and 12 after discontinuation of the 
cyclosporine therapy.  
All patients were regularly monitored: in monthly follow-up visits during the CyA therapy 
and every second month after discontinuation. The activity of UC and the presence of adverse 
events were carefully assessed at each visit, and laboratory findings were entered into the 
clinical record. The side effects that led to discontinuation of the therapy were categorised as 
major, while others were categorised as minor. To compare results and eliminate additive 
effects of corticosteroids on the lipid profile, we used control patients treated with infliximab 
and concomittant steroids. There were 24 patients in the control group, with similar clinical 
characteristics to the cyclosporine-treated group (Table 7.) 
Categorical data were statistically analysed using Pearson‟s chi-square test, Fischer‟s exact 
test, or one-sided Fischer‟s exact test. The effects of cyclosporine therapy on serum 
cholesterol, triglyceride and creatinine levels were examined with mixed-design variance 
analysis (ANOVA) models with time as repeated measures (within-subject) factor and both 
group and side effects as between-subject factors. Pairwise comparisons were performed on 
estimated marginal means by considering the presence or absence of interaction; p-values 
were corrected by the Holm-Sidak method.
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Table 6. The demographics of the 
patients  treated with cyclosporine 
                              
 
Table 7. The demographics of the 
control group. 
Gender(female/male) 
 
14/11 
Mean age at diagnosis 
(years) 
30.8 
(15-
52) 
Left-sided colitis/extensive 
colitis 
10/15 
Concomitant azathioprine 16 
Mean age at start of 
cyclosporine therapy (years) 
39.2 
(19-
67) 
 
Mean disease duration at the 
beginning of cyclosporine 
therapy(years) 
9.2 (1-
32) 
Mean duration of biological 
therapy(months) 
12 
 
 
 
 
 
 
Gender(female/male) 
 
39/33 
BMI (kg/m²) 
 
23.6 
(15.2-
38.3) 
Mean age at diagnosis 
(years) 
31.8 
(14-69) 
Mean disease duration 
(years) 
13.5 (3-
42) 
Left-sided colitis/extensive 
colitis 
27/45 
Previous corticosteroid 
therapy 
39 
 
Concomitant azathioprine 26 
Mean age at start of 
cyclosporine therapy 
(years) 
40.3 
(15-72) 
 
Mean disease duration at 
the beginning of 
cyclosporine therapy(years) 
8.6 (0-
40) 
 
Mean duration of 
cyclosporine 
therapy(months) 
9.6(0.1-
60) 
 
Mean dose of 
cyclosporine/bwkg (mg) 
4.7 
 
Mean trough level of 
cyclosporine (μg/ l) 
193.18 
 
Mean peak level of 
cyclosporine (µg/l) 
866.04 
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7. RESULTS 
7.1.  Study I: Relapse of IBD and C. difficile 
7.2.1. Infection rates and patient follow-up 
Out of the 139 enrolled patients, 76 subjects were diagnosed with UC and 63 with CD. More 
patients with UC participated in the relapse group than CD patients (51 vs. 38 subjects). The 
number of CD and UC patients were approximately equal (24 vs. 25 subjects) in the control 
group. The mean value of the CDAI was 227.89 points (in the range of: 160 to 450) and the mean 
value of the pMayo in the case of UC was 5.21 (in the range of: 3 to 9) points. The most frequent 
disease locations in the relapse cohort were left sided or pancolitis in the case of UC, and pure 
colonic and the ileocolonic in the case of CD. Half of the patients were on immunomodulatory 
therapy in the relapse group (48.8%) and also in the control group (53.1%).  
Bacteria or fungi were identified in 51 of 90 faecal samples taken from relapsing patients. On the 
other hand, 14 patients had positive microbiological stool findings in the control group in 
remission. Overall, C. difficile Toxins was found in 40.3% of the cases with IBD. 46 participants 
with positivity of C. difficile A and B Toxins had been isolated among the patients in relapse 
(51.1%), while CDP was observed in 10 patients (20.4%) in the remission group. Other causes of 
microbiological positivity in the relapse group were due to the presence of Candida species 
(seven subjects with C. albicans, one with C. glabrata and one with Saccharomyces cerevisiae) 
in all except one subject, who had a Salmonella infection. Candida subspecies occurred in five 
patients in remission (four with C. albicans and one with C. glabrata and Geotrichum candidum 
simultaneously). In five cases we found simultaneously presence of C.difficile and Candida in the 
relapse group and in two cases in the control group (Table 8.). A significant difference was 
revealed between the relapse and the control group regarding the microbiological findings and 
positive cases of C. difficile (where p=0.0027 and p<0.001). 21 subjects in the relapse group had 
previous CDP in their medical history, although only 12 of the currently infected patients were 
positive in the past. Eight patients had recurrent or sustained (over 4 weeks) CDP. 10 of the 
control subjects had CDP previously, but only four of currently C. difficile-positive subjects had a 
medical history of CDP. We did not find a difference between CD and UC regarding positive 
microbiological examination findings or CDP (30 subjects with UC and 27 with CD). There was 
no correlation between a medical history of previous CDP positivity and a current C.difficile 
positivity (where p=0.21). 
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Table 8. Infection rates among patients with relapse and remission. Mixed infections occurred in 
assessed faecal samples, not just in relapse cohort, but in patients with remission also. 
 Relapsing group (n=90) Control group (n=49) 
Positive microbiological findings 51 14 
C.difficile Toxin A, B 46 10 
Candida 8 5 
Mixed C.difficile and Candida 5 2 
Salmonella 1 0 
 
There was no significant connection between disease extension, EIMs, perianal involvement, 
smoking, age, gender, disease duration, immunosuppression and proton-pump inhibitor use and 
CDP. Previous antibiotic use was similar in both groups (20% in the relapse group and 20.4% in 
the control group), although it was more frequent among C.difficile-positive subjects. Therefore, 
previous antibiotic use was shown to have a connection to CDP (p=0.033), but other assessment 
factors did not predict the presence of Cl.difficile Toxins. 
Patients in whom C. difficile Toxins had been detected in the relapse group were treated with 
metronidazole. A combination of antibiotics was used, or a substitute was used for metronidazole 
(rifaximin, ciprofloxacine or vancomycin) in case of metronidazole inefficiency, or if repeated 
stool examinations continued to be positive. Three patients needed hospitalisation in a specialist 
Department of Infectology due to a therapy-resistant case of CDP. However, reasonable 
administration of a supplementary therapy or a modification of the maintained treatment was 
sufficient in 65.9% of the cases (oral or topical corticosteroids, 5-ASA and anti-TNF-therapy). 16 
subjects required hospitalisation because of a flare-up. 46 participants who relapsed achieved a 
clinical remission within 8 weeks; the effectiveness of the therapy was not associated with initial 
levels of FC or MMP-9, neither in the relapse cases, nor in the CDP cases. 
7.2.2. Laboratory Findings 
The mean values of CRP in the relapse and the control group were 23.52 mg/L (in the range of: 1 
to 202.6 mg/L) and 6.54 mg/L (in the range of: 1 to 40.8 mg/L), respectively. CRP was slightly 
higher in those with CD than in those with UC (the mean values of which are: CD: 26.02 mg/L 
vs. UC: 21.01 mg/L), but on the other hand, this difference was greater in the control group (the 
mean values of which are: CD: 9.37 mg/L vs. UC: 3.56 mg/L). The mean values of the leukocyte 
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count, the thrombocytes, the serum Fe
+
 and the hematocrit levels were 10.05 G/L, 333.6 G/L, 
11.2 μmol/L and 39% in the relapse group.  
7.2.3. Fecal calprotectin and matrix-metalloproteinase-9 levels 
The mean value of FC in those in relapse was significantly higher compared to the control group 
(with a mean value of: 1292.5 μg/g vs.216.11 μg/g; where p<0.001). Interestingly, FC showed 
greater values in relapsing patients without CDP (with the mean value of: 1457 μg/g) vs. 
relapsing patients with positive microbiological stool examination (with the mean value of: 
1152 μg/g), but in the Wilcox rank test with continuity correction, there was no significant 
difference between a C. difficile positive and negative population (Table 9.).   
Similarly to FC, faecal MMP-9 levels were higher in the relapse group (11.77 ng/mL; in the 
range of: 0 to 168.79 ng/ml) compared to the control group (3.46 ng/mL; in the range of: 0 to 
22.29 ng/mL; where p=0.001). We found a definite difference between the mean values in cases 
of CDP and microbiological negative cases (8.08 ng/ml vs.16.42 ng/ml) in the relapse cohort; 
however, statistical analysis did not confirm the difference (Table 9.).  
Table 9. The mean values of FC and MMP-9. 
 Mean value of FC (µg/g) Mean value of MMP-9 (ng/ml)  
 
 
))9(()()(ng/mL) 
Relapsing group 1292.5 11.8 
...with infection 1152 8.07 
...without infection 1457 16.4 
Control group 216.1 3.46 
 
7.2.  Study II: Clinical manifestations of Blastocystis sp. infection                       
7.2.1.Frequency of Blastocystis spp. 
4567 faecal samples from 3255 patients from the clinics at the University of Szeged were 
analysed at the Department of Clinical Microbiology, Szeged, between January 01, 2005 and 
May 01, 2013. Blastocystis sp. infection was discovered in 275 of 4567 faecal samples (196 of 
3255 patients) – the occurrence of Blastocystis sp. infection was 6% in the symptomatic patients 
who required medical attendance in that period. 
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Eighty of 1471 patients tested positive for Blastocystis sp. at our clinic during this 8-year period, 
representing 5.4% of all stool samples sent during that time from our clinic to be examined for 
the presence of protozoa. 
7.2.2. Results of stool microbiological examination 
Of the faecal specimens, 41.1% contained few Blastocystis sp. cells, 5.5% of specimens 
contained a moderate amount and 53.4% contained a high number of the parasites. In 18.75% of 
the cases other microorganisms were also present besides Blastocystis sp., such as 
Campylobacter jejuni, Campylobacter lari and Clostridium difficile, among fungi Candida 
albicans, Candida glabrata and Geotrichum candidum, as well as other parasites such as 
Entamoeba histolytica and Entamoeba coli (Table 10). Seven of those 15 patients had great 
number of Blastocystis sp. cells in stool samples, and 6 individuals had low numbers of this form, 
therefore the number of Blastocystis sp. cells in co-infections did not make a difference. 
However, every subject had symptoms that improved after antimicrobial therapy. Only one 
patient with gastrointestinal co-infection (C. glabrata) had skin symptoms.  
Table 10. Microorganisms detected in the same stool samples together with Blastocystis sp. 
Microorganism in stool: Number of cases 
Campylobacter jejuni 3 
Candida albicans 3 
Clostridium difficile A and/or B toxin(s) 2 
Campylobacter lari 1 
Non-toxin-producing Clostridium difficile  1 
Candida glabrata 1 
Geotrichum candidum 1 
Entamoeba coli  1 
Entamoeba histolytica and Clostridium 
difficile A and/or B toxin(s) 
1 
Entamoeba histolytica with Geotrichum 
candidum 1 
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7.2.3. Blastocystis sp. and skin manifestations 
Nine out of 80 people had accompanying skin manifestations. We did not find a statistically 
significant difference regarding age and gender between individuals with vs. without skin 
manifestations (p=0.73 and p=0.34, respectively).  
73.75% of the 80 patients indicated that they had gastrointestinal symptoms: 40 patients 
complained of abdominal pain, 17 with blood in their stool, while other symptoms, such as 
meteorism (15 subjects), weigh loss (8 subjects), perianal pain or itching (6 subjects), passing 
stool with mucus (5 subjects), vomiting (2 subjects) and fever (2 subjects) were less frequent. The 
prevalence of abdominal pain in the cohort without skin lesions was higher compared to those 
patients with skin problems (p=0.007). 
Full blood count, including thrombocytes, leucocytes (eosinophils, basophils, neutrophils, etc.), 
was within a normal range, except for CRP, which showed elevated levels (at a mean value of 
13.89 mg/l, in a range between 1 and 89.9 mg/l) at admission.  
Significant differences were revealed between patients with and without skin manifestations 
regarding laboratory findings, namely the value of CRP (p=0.038), leucocytes (p=0.024), 
neutrophil granulocytes and its percentage ratio (p=0.007, p=0.012), thrombocytes (p=0.002) and 
RDW (Red blood cell Distribution Width /RDW/; p=0.025) were significantly higher in patients 
with skin manifestations. The value of lymphocyte (p=0.011) and monocytes (p=0.023, p=0.011) 
and their percentage ratios were higher in subjects without skin lesions. Interestingly, we didn‟t 
find a significant difference in eosinophil counts.  
The diagnosed accompanying conditions (e.g. gastroesophageal reflux disease /GERD/, weight 
loss, and hepatomegaly) of a Blastocystis sp. infection are summarised in Figure 1. Prevalence of 
IBD was 9% among Blastocystis sp. positive patients. Weight loss, lactose intolerance and GERD 
were significantly more common in patients with skin lesions vs. without skin manifestations 
(p=0.04, p=0.04, p=0.02, respectively). Seven patients were treated with antibiotics previously, 
due to other infections (prostatitis, pharyngitis, etc.) No association was found between previous 
antibiotic use and the occurrence of skin lesions. 
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Figure 1. Common conditions associated with Blastocystis sp. positivity in our patients 
 
Skin manifestations (Picture 1.) occurred in 9 patients, predominantly with females (7 out of 9 
patients). Those were urticariform – itching, tiny rashes 1-2 mm in diameter – in 5 patients, and 
reddish-brown infiltrated papules, sometimes with hyperaemic and irregular borders, in 3 
subjects. In one patient a nutritive allergy was found by a dermatologist. Only one patient with 
UC had skin rashes. 
Picture 1. Numerous, 5-10 mm diameter sized, sporadically confluent, itching, urticariform-
papular skin lesion on back and gluteal region. 
 
 
Eight patients with cutaneous symptoms received metronidazole, although 3 needed an additional 
antimicrobial agent due to co-infection (e.g. Borrelia burgdorferi, Mycoplasma pneumoniae and 
Escherichia coli infections.) One patient had doxycycline therapy. With regard to gastrointestinal 
Coeliakia 
3% 
Colon polyp 
3% 
Cholecystolithiasi
s 
4% Colon tumor 
6% 
Hiatus hernia 
6% 
Lactose 
intolerance 
6% 
Steatosis 
hepatis 
8% 
IBD 
9% 
Urticaria 
11% 
Diverticulosis 
12% 
IBS 
12% 
GERD 
20% 
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symptoms and skin manifestations, all patients became asymptomatic after antimicrobial 
treatment.  
40 of the patients had persistent gastrointestinal symptoms, both with and without skin lesions, 
justifying the initiation of antimicrobial therapy. We used metronidazole in 92.5% of the cases, 
but 10 patients needed combined therapy or a switched antimicrobial therapy, using mainly 
rifaximin or sulphametoxazole and trimethoprim due to synchronous infections and the 
ineffectiveness of metronidazole.  
 
7.3. Study III: Efficacy of influenza vaccination 
7.3.1. Patient characteristics 
209 IBD patients (127 with CD, 82 with UC) were eligible and enrolled in the study. 156 patients 
received influenza vaccination, while 53 patients (control group) refused the vaccine – the willing 
to vaccination was 66.3%. Whole virion vaccine was given to 57; split vaccine was given to 99 
patients. The mean age of the vaccinated patients was 27.9 years; 84 were women, 72 were men. 
In the control group the mean age was 30.7 years, 29 were women, 24 were men. Of the 156 
vaccinated patients, 98 had CD, 58 had UC. Median disease duration was 9 years for CD (IQR 5-
13), and 9 years for UC (IQR 4-15.8). Of the control subjects, 29 had CD and 24 had UC. Median 
disease duration was 7 years for both CD (IQR 5-14), and for UC (IQR 4.5-12). 
Of the 156 vaccinated patients 115 patients received immunosuppressive therapy. The non- 
immunosuppressive group of vaccinated subjects was composed of 41 patients. Of the 53 control 
subjects immunosuppressive therapy was given to 32 patients. Twenty-one patients were free of 
immunosuppressive therapy. 8.3% of the patients are regularly vaccinated against seasonal 
influenza virus. 39 patients (21.5%) received the last vaccination at the a year, 25 patients 
(13.8%) within 3 years and 3 patients (1.7%) within 5 years. 63% of the patients received the last 
vaccination more than 5 years ago.  
 
 
 
40 
 
 
7.3.2. Antibody titers for Influenza A and B subtypes 
The values of preimmunisation antibody levels of influenza A and B titers varied between 33.8-
341.3 RU/ml and 45.8-248.7 RU/ml, respectively. The antibody values of the postimmunisation 
levels of influenza A and B titers varied between 43.9-301.5 RU/ml and 58.2-216.9 RU/ml. The 
postimmunisation antibody titers of Influenza A and B subtypes significantly increased in 
patients immunized with split virion vaccines (mean increase of antibody levels was 13.8 RU/ml 
for Influenza A and 17.4 RU/ml for Influenza B) compared to control subjects (mean increase of 
antibody levels was 9.4 RU/ml for Influenza A and 7.3 RU/ml for Influenza B) (p=0.045 for 
Influenza A and p=0.03 for Influenza B). Although the increasing tendency of titers measured at 
week 6 was also observed in control patients it was not significant.  
The antibody titers of Influenza A and B significantly increased after the administration of split 
vaccine compared to whole virion vaccines (p=0.03 for Influenza A and p<0.001 for Influenza 
B). The postimmunisation antibody titers of Influenza B also increased significantly after 
administrating split vs. whole virion vaccine in patients treated with anti TNF-α (p=0.002). 
However, the study was not powered to directly compare the alterations in the postimmunisation 
antibody titers in vaccinated and control patients treated with thiopurines and anti-TNF-α alone 
or in combination.  
7.3.4. Effect of vaccination on IBD activity 
During the 4 months follow-up period, 1 of the control subjects and 21 of the vaccinated patients 
(8 CD, 13 UC) developed a flare up with an increased diarrhea or bloody stool. The mean CDAI 
at the flare up was 273 points, the mean pMayo score was 4 points. This was observed with both 
types of vaccine; however, of the 21 patients with flare up, 15 received IDFlu9 split virion 
vaccine. The flare up developed a mean of 6 weeks after the vaccination. These 21 patients were 
followed up for 4 months additionally. Absence of flare was observed in 3 weeks. Disease 
activity resolved spontaneously in 11 patients, 2 patients needed corticosteroids, 5 antibiotics. 
Three patients remitted after the following biological therapy.  
7.3.5. Side effects and development of influenza-like symptoms 
26 patients developed local reaction (pain, redness, warmth, swelling) after vaccination, 32 had 
systemic symptoms (shivering, subfebrility, fever, fatigue, malaise, headache, muscle pain) 
during the first week. The most common local reaction after any type of vaccine was redness at 
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the injection site, reported by 11%. The local reactions disappeared within 48 hours in every case. 
The most common systemic reactions were common cold and sore throat in 39.7 and 28.8% of 
the patients. Systemic reactions resolved within a week. 
Upper respiratory tract infection like symptoms more frequently occurred within the first week in 
vaccinated vs. control patients (31.4% vs. 9.4% p=0.002). During the further follow-up, no 
difference was shown between the two groups. Influenza-like symptoms occurred in 7 of the 
vaccinated and 1 of the control patients in the first 4 weeks, and 6 of the vaccinated and 3 of the 
controls between the 5 and 16 weeks. These influenza-like symptoms developed in 12 CD and 5 
UC patients and all but one was on immunosuppressive therapy in both vaccinated and control 
group. Local and systemic reactions were more common in patients vaccinated with IDFlu9 split 
vaccine vs. Fluval AB (p<0.001). The local and systemic side effects developed after the 
influenza vaccination are summarized in Table 11. 
 
Table 11. Local and systemic adverse events after vacctination. 
Effect Fluval AB (n=57) IDFlu9 (n=99) 
Local reaction   
Any reaction, n (%) 2 (3.5) 24 (24.2) 
Pain, n (%) 1 (1.8) 11 (11.1) 
Redness, n (%) 1 (1.8) 16 (16.2) 
Swelling, n (%) 1 (1.8) 14 (14.1) 
Itching, n (%)  6 (6.1) 
Systemic reaction   
Any reaction, n (%) 28 (59.1) 70 (70.7) 
Shivering, n (%) 0 3 (3.0) 
Fever ≥38oC, n (%) 0 16 (16.2) 
Unusual fatigue, n (%) 1 (1.8) 2 (2.0) 
Malaise, n (%) 2 (3.5) 13 (13.1) 
Headache, n (%) 4 (7.0) 18 (18.1) 
Muscle pain, n (%) 5 (8.8) 11 (11.1) 
Arthralgia, n (%) 1 (1.8) 7 (7.0) 
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Sore throat, n (%) 15 (26.3) 30 (30.3) 
Common cold, n (%) 15 (26.3) 47 (47.5) 
Sneeze, n (%) 12 (21.1) 22 (22.2) 
Coughing, n (%) 6 (10.5) 21 (21.2) 
Subfebrility, n (%) 10 (17.5) 8 (8.0) 
Vertigo, n (%) 0 4 (4.0) 
 
7.4. Study IV: Bolus administration of steroid therapy 
7.4.1. Patient characteristics, clinical response 
During the study period, 20 patients with IBD (5 with CD, 15 with UC) were enrolled. At day 5, 
all but one patient achieved clinical remission. One patient proved to be refractory to intravenous 
steroid and needed rescue therapy therefore she was excluded because of treatment failure. 
Methylprednisolone was tapered weekly and stopped at week 12 in these 19 patients who could 
complete the study. The clinical characteristics of the participated 19 patients are presented in 
Table 10. Ten patients had already been diagnosed with IBD, while the remaining 9 patients were 
at disease onset. Although the male/female ratio was higher in Group II, baseline clinical 
characteristics of patients did not differ significantly between the two treatment groups. CDAI 
and pMayo score showed decreasing pattern in both groups during the steroid therapy.  
CDAI and pMayo score decreased to a median value of 21 and 0 (median CDAI 35, median 
partial Mayo score 0 in Group I and 12 and 0 in Group II) at the end of the steroid therapy. 
Median CDAI and pMayo scores during the „conventional" and the „bolus" methylprednisolone 
treatment periods are indicated in Table 12. The mean value of CRP, ESR, leukocytes and 
thrombocytes after steroid therapy were 7.4 mg/l, 9.7 mm/h, 7.935 G/l and 238 G/l. The effects of 
bolus therapy on the clinical and laboratory parameters of disease activity did not differ from the 
conventional administration. The patients in both groups had not relapsed at the discontinuation 
of steroid therapy.  
 
 
 
43 
 
 
 
Table 12. Median CDAI and pMayo scores during the „conventional" and the „bolus" 
methylprednisolone treatment periods 
 
 
 
 
 
 
 
 
 
7.4.2. Changes in adrenal glands hormone secretion, in the lipid and bone metabolism 
after methylprednisolone therapy 
In Group I, BMI increased significantly at the end of the steroid therapy (p=0.008). In Group II, 
no difference was observed in BMI before and after the steroid therapy. Total body composition 
analysis showed significant decrease in BMD in Group I (p=0.032). Body fat percent showed a 
tendency to be higher at the end of steroid therapy in Group I, although the difference was not 
significant.  
Considering the laboratory parameters, serum cholesterol level increased significantly in Group I 
patients after steroid therapy (p=0.028). The decrease in serum cortisol level was more 
remarkable in Group I vs. Group II after steroid therapy (p=0.02 and p=0.055). Figure 2 
summarizes the significant changes in the examined parameters. 
 
 
  Group I Group II 
Weeks Median CDAI Median pMayo Median CDAI Median pMayo 
0 204 6.2 164 5.1 
2 184 5 152 4 
4 146 3.4 126 2 
6 86 1 90 0 
8 72 0 64 0 
10 68 0 48 0 
12 35 0 12 0 
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Figure 2: Significant changes in the examined parameters after 12-week methylprednisolone 
therapy in Group I and II 
 
No changes were detected in the waist and hip circumference, T and Z scores, electrolytes, liver 
and renal function, serum glucose, serum calcium, triglyceride, DHEA, TSH, PTH and ß-
crosslaps before and after the steroid therapy neither in Group I, nor in Group II.  
7.4.3. Steroid-related side effects 
The most common side effects occurring during the therapy were the Cushingoid appearance, 
development of acne, fatigue, gastrointestinal complaints. Side effects were presented in 5/9 
(55.6%) vs. 4/10 (40%) of the patient in Group I and II. Cushingoid appearance did not occur in 
Group II. The side effects are summarized in Table 13. 
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Table 13. Side effects developed in patients in Group I and II 
Group I Group II 
 Side effect  Side effect 
Patient 1 Cushingoid 
appearance 
Patient 1 Acnes 
Patient 2 Cushingoid 
appearance 
Patient 2 Acnes 
Patient 3 Acnes Patient 3 Arthralgia 
Patient 4 Acnes 
Arthralgia 
Patient 4 Fatigue 
Hypertension 
Patient 5 Cushingoid 
appearance 
Arthralgia 
Fatigue 
Nausea 
Stomatitis 
  
 
7.5. Study V: Side effects of cyclosporine A therapy 
The average duration of cyclosporine therapy was 9.6 months. The mean oral dose of 
cyclosporine was 4.7 mg/kg, the mean fasting level of cyclosporine was 193.18 μg/L and the 
mean 2 hours-post-dose level was 866.04 μg/L. 
Table 14.  Mean levels of serum total cholesterol, triglyceride and creatinine. 
 
Before cyclosporine 
therapy 
During cyclosporine 
therapy 
After cyclosporine 
therapy 
Mean level of serum total 
cholesterol (mmol/l) 
172.9 
 
235.5 
 
196.2 
 
Mean level of serum total 
triglyceride (mmol/l) 
127.4 
 
155.7 
 
112.4 
Mean level of serum 
creatinine (µmol/l) 
0,81 0.83 
 
0.78 
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Side effects occurred in 52 patients (72.2%) during the therapy (Figure 3.). The most frequent 
side effects were hypertension (15.23%), tremor (13.8%), hypertrichosis (9.72%), myalgia and 
muscle cramping (11.1% and 4.16%, respectively) and numbness of legs (5.5%). Nephrotoxicity 
or hepatotoxicity occurred in 6 patients (8.33%). Increased serum cholesterol and triglyceride 
levels were detected in 47.2% and 19.4% of the patients, respectively. Major side effects 
resulting in discontinuation of the cyclosporine therapy occurred in 21 patients. The most 
frequent major side effects were adverse muscle reactions (47.6%) and hypertension (38.1%), 
followed by gastrointestinal side effects including liver enzyme abnormalities (23.8%) and skin 
side effects (14.3%). Major side effects are detailed in Figure 4. 
 
Figure 3. Side effects occured in our enrolled patients. 
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Figure 4. The major side effects during cyclosporine therapy. 
 
The mean value of serum cholesterol levels (Table 14.) measured before starting the cyclosporine 
therapy was 172.9 mg/dL (range: 84.9 -331.6 mg/dL) and in the control group, it was 200 mg/dL 
(115.8-370.6 mg/dL). During the therapy, serum cholesterol levels increased to the mean value of 
235.5 mg/dL (range: 134.4-370.6 mg/dL), while this value remained within normal range in the 
control group (200 mg/dL, range: 137.8-301.5 mg/dL). After discontinuation of the cyclosporine 
therapy, serum cholesterol levels decreased to the mean value of 196 mg/dL (range: 88-
323.2 mg/dL) (Figure 5.). Decreased levels of serum cholesterol were detected in patients treated 
with combined   infliximab-steroid group after cyclosporine therapy (190.3 mg/dL; range: 110.8-
277.6 mg/dL). Statistically, serum cholesterol levels increased significantly during the therapy 
and remained higher for one year after the discontinuation of CyA (p<0.001, p<0.001). 
Furthermore, serum cholesterol levels measured during the cyclosporine therapy were 
significantly higher than those after the discontinuation of the drug (p<0.001). In the cyclosporine 
group, cholesterol levels were considerably higher during therapy than in the control group 
(p<0.001). 
Cholesterol levels measured after cyclosporine therapy were found to be significantly higher in 
patients with an adverse reaction (p= 0.045) vs. patients without adverse reactions. In both 
groups, serum cholesterol levels showed a significant elevation at the time of the cyclosporine 
therapy (p<0.001) and afterwards (p<0.001; Figure 6.). No difference was found between patients 
who had only minor side effects during therapy and those who had none, but those patients who 
had major adverse effects had higher cholesterol levels after therapy (p=0.013). 
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Figure 5. Serum cholesterol levels during study period.
 
 Figure 6. Cholesterol levels after cyclosporine therapy were significantly higher in patients with 
an adverse reaction vs. patients without adverse reactions. 
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Elevated total cholesterol levels were noted in 65.4% of the patients with detectable side effects. 
Increased serum cholesterol levels (mean value of 270.6 mg/dL) were detected in 54.5% of the 
patients with hypertension. Hypertension was defined as systolic pressure at or above 140 mmHg 
and diastolic pressure at or above 90 mmHg.  
One of the most common adverse reactions was tremor. Increased serum cholesterol levels were 
noted in 70% of those developing tremor (mean value of 283.4 mg/dL). Neurological side effects 
(tremor, sensational abnormalities) occurred in 25% of the patients.  
Myalgia was also a frequent side effect; 5 of 8 patients with myalgia had a high serum lipid 
profile (mean total cholesterol of 252.5 mg/dL). A significant correlation was found between 
muscular side effects (myalgia, cramping of extremities, numbness of legs) and elevated serum 
triglyceride levels (p=0.038).  
Serum triglyceride levels were elevated in 19.4% of the patients. The mean serum triglyceride 
levels before, during and after cyclosporine therapy were 127.4 mg/dL, 155.7 mg/dL and 
112.4 mg/dL, respectively (Table 14.). No difference was found in triglyceride levels compared 
to the control group. 
Serum creatinine levels were slightly elevated in only 3 patients during cyclosporine therapy 
(Table 14.). No significant correlation was shown between cyclosporine therapy, the frequency of 
side effects and serum creatinine levels. In addition, creatinine levels did not differ between the 
cyclosporine and the control group. 
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8. DISCUSSION 
 
It is well-known that the infection rates in patients with IBD is greater than in the normal 
population; infectious agents are involved in the aetiopathogenesis, but it can also initiate a 
relapse of the IBD (100). Some studies suggest that the aetiology of IBD with altered intestinal 
microbiome is a result of innate genetic defects in the intestinal epithelial and mucosal barriers, 
which can contribute to bacterial translocation. In addition, the aetiological background may 
involve a microbial imbalance in the intestine or dysfunction in the intestinal inflammatory 
cascade, leading to pathologic proliferation of cytokines (101). Although an exact aetiology of 
IBD has not been confirmed yet, the importance of microorganisms in the intestine is obvious. 
Due to its significance in daily routine, infection rate during an IBD relapse and the clinical 
utility of faecal inflammatory markers were assessed in our study. IBD is an independent risk 
factor of CDP, mainly UC patients are susceptible to infection, and thus microorganisms have 
considerable significance in patient management (20, 102,103,104). In our study, the UC/CD 
ratio in the C.difficile cohort was approximately equal. 
CDP (51.1%) and Candida (10%) infections were the most frequent results of faecal 
microbiological examinations in our relapse cohort, suggesting an imbalance of intestinal 
microflora and some connection between flare-ups of IBD and CDP.  A differential diagnosis of 
a relapse and CDP is difficult in some cases; furthermore, both can occur at the same time, thus a 
faecal microbiological examination and tests for both Toxins A and B are recommended in the 
event of a flare-up, as the evidence-based consensus of European Crohn‟s and Colitis 
Organisation also suggests (20).  C. difficile is mostly a community-acquired infection, thus it 
mainly develops among our outpatients; however, hospitalisation, colectomy and mortality rates 
are higher in a population with CDP.  
Colonising microbes inhabiting the intestinal mucosa are important for normal intestinal function 
and homeostasis. Dysbiosis develops when the composition of intestinal microbiome is 
unfavourable, and this condition may lead to various diseases. Altered microbiome may be a 
cause or consequence of a disease, but it may develop parallel with an abnormal condition (105). 
The balance of intestinal homeostasis is a sensitive system of intestinal microbiota, epithelium 
and immune cells (106). An alteration of colonic microbiota has been suggested in IBD (107), 
given that intestinal flora is altered in patients who relapse, which in turn allows the unopposed 
51 
 
 
proliferation of C.difficile and Candida. The frequency of the community-acquired CDP has been 
increasing worldwide with incidence rates of 3 to 40% (58,108,109,110). The occurrence of CDP 
was remarkably high in our IBD patients (40.3%); in addition, the frequency of Candida 
infections was 10% among the enrolled subjects. Presence of Candida in gastrointestinal tract is 
commonly benign, but in susceptible individuals with low level of inflammation (eg. IBD) may 
promote colonisation that promotes further inflammation, thus may become a trigger factor (111). 
The role of C.difficile may be the similar.  
The disease course of a C.difficile infection can be extremely serious, even life-threatening 
complications may occur, which is confirmed beyond a doubt by the mortality rate of hospitalised 
IBD patients with a C.difficile infection (112). Although, CDP was not severe in most of the 
cases in our study: half of the subjects showed signs of clinical remission within 8 weeks of 
follow-up, and serious complications did not occur during the tenure of the study. However, 
hospitalisation was needed in 19 of 51 cases, most of them because of a severe flare-up requiring 
intravenous steroid treatment. It seems that CDP is also a trigger and an additive factor; however, 
the isolated treatment of the infection does not affect symptomless patients in the vast majority of 
the cases. In some studies, antimicrobial and immunomodulator agent-exposure has been shown 
to increase the possibility of a C.difficile infection and carriage (61). Basically, any type of 
antibiotic may be linked with the manifestation of a C.difficile infection; however, the antibiotics 
most commonly connected to an occurrence of infection include penicillins, clindamycin, 
cephalosporines and fluoroquinolons (113). Regardless, antibiotic use for IBD patients in general 
seems to be a critical risk factor for the development of a CDP, as our results showed (where 
p=0.03). The use of immunomodulators specifically has not been confirmed in our study to be 
predictive of a CDP risk, however. The data available on immunomodulators is conflicting; some 
studies showed an increasing risk for CDP (61), although others did not confirm these results 
(114). The number of C. difficile-positive subjects taking immunosuppressants did not differ 
substantially compared to those patients not treated with immunosuppressants (26 vs. 21 
subjects) in our study.  A correlation between CDP and the use of gastric acid-suppressive agents, 
especially histamine blockers and proton pump inhibitors, has been suggested (115,116). 
However, similarly to our own findings (where p=0.65), other observational studies did not yield 
results to support the connection (117). 
A strong correlation between intestinal inflammation and FC has been confirmed in IBD 
(118,119); however, its value can increase in enteral infections also (120,121).  Enhanced levels 
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of MMP-9 have been noted in the intestinal tissue in the case of IBD and seem to be actively 
involved in the inflammatory and remodelling process (122,123).  In this study, levels of FC and 
MMP-9 were measured both in faecal microbiology positive and negative cases; however, we did 
not find a significant difference between those groups regarding the two assessed faecal 
inflammatory parameters. We thought that if the measurement of faecal markers helps in making 
a prompt decision about the need of antibiotics in the treatment of a flare-up, it would be a 
supportive method, since the result of microbiological examinations usually takes a few days, 
which can cause a delay in the initiation of the targeted therapy. Although we observed higher 
levels of FC and faecal MMP-9 in natural relapses than in infection-induced relapses, the 
statistical analysis did not confirm this observation. 
Laboratorial techniques have basic importance in diagnosis of infectious and other organic 
intestinal disorders. However, enteral infections caused by univocal microorganisms may present 
clinical signs and symptoms, e.g. extraintestinal manifestations that make differential diagnostic 
difficulty. Blastocystis sp. is a common intestinal parasite worldwide that often causes atypical 
gastrointestinal symptoms. The prevalence is higher in developing countries and is usually 
connected to poor standards of hygiene, exposure to animals and the consumption of 
contaminated food or water (124). The occurrences of Blastocystis sp. infections spanning the 
time period relevant to our study were an overall 6% in patients treated at the clinics at the 
University of Szeged and 5.4% among patients examined in our clinic and whose data was used 
in this study. Despite this parasite coming into question as a possible causative microorganism of 
some intestinal illnesses, its pathogenicity and clinical significance has not yet been confirmed. 
Some studies reference Blastocystis sp. as a potential pathogen (125), but the role of the 
protozoon in the development of certain intestinal disorders is not fully understood. However, 
data are available about Blastocystis sp. supporting a connection with IBS and IBD (126,127,128, 
129). In the study of Tai et al Blastocystis sp. infection has been confirmed in 12.2% of relapsing 
ulcerative colitis patients (130). Moreover, recently published study suggests that Blastocystis sp. 
subtype 3 can trigger the proliferation of human colorectal cancer cells (131). On the other hand, 
this parasite is also common in healthy individuals, suggesting that it can be a component of 
normal intestinal microbiota (132). Molecular characterisation from symptomatic and 
asymptomatic carriers should help to reveal the clinical implications of this microorganism 
(133,134). Distribution of the 9 subtypes of Blastocystis sp. found in humans seems to be 
dependent on geographic locations. Subtype 3 is the most widespread in every continent except 
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the US, where subtype 1 is the most common (135). We did not assess subtypes of Blastocystis 
sp., because during the time period from that data was used it was not part of routine 
microbiological examinations, furthermore, it currently has no significance in patient 
management and therapy. However, the relevance of the subtypes is deemed worthy of further 
study. 
 Extraintestinal manifestations of Blastocystis sp. infection, such as urticaria and other skin 
lesions, and the role the infection many have in these manifestations have already been described 
in various publications (136,137,138,139,140). In a recent study (141), 13.7% of the patients with 
allergic skin symptoms were infected by Blastocystis sp.; furthermore, no other allergic agent was 
found to offer explanation why the urticaria manifested. The significance of Blastocystis sp. as 
background cause of urticaria was indicated in prospective research from Peru, which revealed a 
connection between symptomatology and Blastocystis sp. positivity; the symptoms in question 
were urticaria, abdominal pain and meteorism (142). Also supporting the connection was the 
gradual disappearance of dermatological symptoms after treatment and eradication of 
Blastocystis (143,144). It has been suggested that cutaneous lesions are immune-mediated, but 
the mechanism is not completely clear (145). In our study, 11.25% of infected patients 
manifested skin symptoms, predominantly the female patients. Disorders were mainly 
urticariform and dermatitis-like lesions. There was no significant difference observed depending 
on the amount of protozoa in the samples; therefore, just a few Blastocystis sp. cells were enough 
to induce a cutaneous manifestation. Skin symptoms improved after specific antimicrobial 
treatment.  
The symptoms of Blastocystis sp. infection are usually nonspecific, and along with other 
symptoms, flatulence, nausea, vomiting and bloating may manifest as a result of this infection. 
Depending on the severity of the infection, everything from mild chronic diarrhoea to acute 
gastroenteritis may occur (67). Jones et al reported fatigue, skin rash and diarrhoea as the most 
frequent symptoms of Blastocystis sp.infection, and suggested connection between Blastocystis 
sp. and chronic gastrointestinal illness (146).  Several variations of signs and symptoms were 
associated with Blastocystis sp. infection in our cohort, ranging from nonspecific intestinal 
symptoms to cutaneous disorders. No specific laboratory parameter was discovered that would be 
indicative of parasite infection, however, elevated CRP and white blood count was shown in 
Blastocystis sp.-associated skin manifestations. Interestingly, we did not find elevated eosinophil 
count in the whole cohort, regardless of whether or not the patients had accompanying skin 
54 
 
 
manifestations. Thus, we can state that eosinophilia is not an obligatory laboratory finding in 
protozoon infections, such as Blastocystis sp., with or without skin lesions. In 18.75% of our 
patients another intestinal microorganism was discovered parallel to Blastocystis sp., e.g.  Ca. 
jejuni, Ca. lari, C. albicans, C. glabrata, C. difficile and E. histolytica. On the other hand, skin 
lesions only manifested with one of them, and symptoms improved after specific antimicrobial 
therapy. Therefore, the causative agent of the skin lesions was presumably the Blastocystis sp. In 
addition, 40% of the enrolled individuals also suffered from additional underlying chronic 
intestinal abnormalities, such as colon tumours, IBD, IBS, coeliac disease, lactose intolerance or 
diverticulosis. Considering the great number of patients with the above mentioned diseases the 
vulnerability of the intestine is suggested to be a risk factor for a Blastocystis sp. infection. Nine 
percent of subjects suffered from IBD among assessed Blastocystis sp. positive population, 
although only one patient with UC had skin manifestations at the time of study period. 
IBD associated infection and its management is a daily routine as our results showed as well; 
therefore, prevention has a significant importance. Prevention should be primary endpoint of 
infection control. However, questions still exist regarding passive immunization of 
immunosuppressed patients.  
Vaccination is a conventional strategy for the prophylaxis of vaccine-preventable infections, 
especially in patients suffering from immune-mediated diseases (147). Our multicentre survey 
revealed that most of the patients are willing to be vaccinated against the seasonal influenza virus 
if it is recommended and administered by the gastroenterologist, although promoting prevention 
and prophylaxis seemed to be underutilized in the previous years. In a survey done in IBD 
patients, only 28% of the patients reported yearly influenza vaccination (148). Possible 
explanations for under-vaccination of IBD patients are unawareness of the increased infection 
risk and concerns about the safety and efficacy of the vaccination. In our study, every patient was 
recommended to be vaccinated and, after detailed consultations, two thirds of them accepted 
vaccination, which indicates that informing and assuring the patients may increase the 
willingness to take the vaccination. Patients on immunosuppression or biological therapy are 
supposed to be at increased risk of influenza (149), thus, annual influenza vaccination is 
recommended for all patients with IBD on immunomodulators (20). It is well-known that the 
majority of the studies examining the efficacy of influenza vaccination in IBD patients have been 
carried out in children. Mamula et al. (78) observed a reduced seroconversion rate and geometric 
mean titre after influenza vaccination in IBD patients receiving immunotherapy compared with 
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healthy controls. Another study found that vaccination responses were similar among children 
with IBD, regardless of immunosuppressive status (79). These studies revealed that vaccination 
against influenza in children with IBD is well tolerated and induces immune response, although 
anti-TNF therapy may selectively impair response to specific serotypes. deBruyn et al. also found 
that children with IBD were less likely to mount an immunogenic response for influenza B 
compared with controls (150). According to our results, the post-immunisation antibody titres of 
both Influenza A and B subtypes were increased in patients vaccinated with split virion vaccines 
vs. control subjects, although the study was not powered to detect differences between the 
different immunosuppressive maintenance therapies.  
Some studies observed an impaired immune response after influenza vaccination in patients 
treated with anti-TNF agents. However, response rates to influenza vaccination in patients treated 
with immunomodulators and biologicals are somewhat conflicting. Andrisani et al. revealed that 
seroprotective titres in the patients were comparable to healthy controls. Seroconvertion rate was 
lower in IBD patients than in healthy controls either on anti TNF-α monotherapy or combined 
with immunosuppressants (80). In a study conducted on patients with rheumatoid arthritis and 
CD, postvaccination geometric mean antibody titres against influenza (A/H3N2 and B) were 
significantly lower in patients treated with anti-TNF (infliximab, adalimumab or etanercept) 
compared with patients not receiving anti-TNF therapy and the healthy controls (151). Our 
results revealed that the increase in post-immunisation titres of only Influenza B subtype was not 
influenced by anti TNF-α therapy – although only in case of the administration of split virion 
vaccines. 
The results about the immune response to split virion vaccine vs. whole virion vaccine also seem 
to be controversial. A study evaluating both split virion and whole virion H5N1 vaccine 
formulations in children revealed that the whole virion vaccine may be immunogenically better 
than the split virion vaccine, confirming the previous findings in adults (152). However, in 
another study, AS03B-adjuvanted split virion or a non-adjuvanted whole virion H1N1 (2009) 
vaccine was used in 943 children and both vaccines proved to be safe and immunogenic (153). In 
Hungary, whole virion vaccines are supported by the Hungarian National Health Fund (OEP), 
and thus these are used routinely in the clinical practice. However, in this study, we had the 
opportunity to assess the efficacy of the less immunogenic split virion vaccines. Our results 
demonstrated significantly higher post-immunisation antibody levels in case of split virion 
vaccines. The frequency of the side effects was higher in case of split vaccines; however, it is 
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important to note that no severe adverse reactions occurred. The rate of influenza-like infections 
was quite low during the follow-up period and did not differ significantly in vaccinated vs. 
control subjects. Influenza-like symptoms were more likely to develop in patients with 
immunosuppressive therapy in both vaccinated and control patients. 
Antibody response is an integral component of normal immunity. Successful humoral immunity 
depends on cellular interactions and it is not unusual to observe deficient antibody responses in 
immunologically compromised hosts. Age and concomitant therapy may also influence immune 
response after influenza vaccine – thus that it is very difficult to assess whether in vitro immunity 
corresponds to in vivo immunity. In a study from the „80s (154), 14 monkeys received a trivalent 
influenza vaccine and antibody response was determined based on a change in plasma antibody 
content before and after the vaccine. In vitro anti-influenza antibody synthesis was found to 
correlate well with the in vivo response. Ershler et al. also measured the antibody response in 
young and elderly volunteers after in vivo and in vitro immunisation with trivalent influenza 
vaccine. After in vivo immunisation, plasma antibody levels and in vitro synthesis capabilities 
significantly increased in the young subjects. The capacity for in vitro immunisation was also 
greater in the young, but the difference did not reach statistical significance and there was no 
correlation with in vitro immunisation potential and the response after in vivo vaccination (155). 
It is not in question whether inactivated influenza vaccination is recommended yearly for patients 
with IBD. Despite the initial results, a number of studies have shown that immunosuppressive 
and anti-TNF therapy are safe and effective in regard to the response to annual trivalent 
inactivated influenza vaccination. In this cohort, split vaccines seemed to be more effective than 
whole virion vaccines, and split vaccines also resulted in an increase in post-immunisation titres 
of Influenza B subtype besides anti TNF-α therapy.  
The use of immunosuppressants revolutionized the therapy of immuno-mediated and 
autoimmune diseases; however, this type of drugs increases not only the probability of infections, 
but also other side effects (156,157). For the past 30 years, corticosteroids have been the 
mainstay of therapy in patients with moderate to severe active IBD (158). Intravenous therapy 
generally produces rapid improvement of symptoms. Once improvement has been achieved, 
corticosteroids should be tapered gradually per week until the drug is discontinued. The mean 
goal of IBD therapy is to decrease the steroid-related side-effects and to minimize steroid 
dependency with the development of new series of anti-inflammatory glucocorticoids with 
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enhanced topical potency and less systemic activity such as budesonide or beclamethasone (159). 
Less attention is paid to the dosing of steroids, although it seems to be also important.  
Although are no trials between different steroid-tapering regimens, the goal in the daily practice 
is to get patients off corticosteroids within 12 weeks and maintain disease remission. 
Alternatively, alternate-day corticosteroid therapy can also be used in patients with refractory 
Crohn's disease – even for longer time (160). However, some available evidence suggested that 
the manner of corticosteroid tapering probably did not change the long term outcome in IBD 
(161). Use of “bolus-administered” steroids is a novel possibility to optimize the therapy. Bolus 
administration is actually an untested manner that has been anecdotally recognized to be more 
effective than the conventional use of steroid therapy. Multiple doses of steroids were previously 
shown to cause more adverse effects than a single dose (162). In a single-center, double-blind 
trial performed by Bossa et al. patients with a severe attack of UC were scheduled to receive 
equal iv. doses of methylprednisolone, randomly given as either a bolus injection administered 
twice daily or continuous infusion (163). Methylprednisolone given as a continuous infusion was 
no better than bolus administration in terms of efficacy and safety. The aim of bolus steroid 
therapy is to get quicker and stronger anti-inflammatory effect. Giving a higher dose of 
methylprednisolone, an immediate profound anti-inflammatory effect is supposed to be achieved 
with lower toxicities and no prolonged suppressive effect on the hypothalamic-pituitary axis.  
Our results did not show any significant difference according to the disease outcome between the 
two administration types at the end of the therapy and at follow up times for any of the clinical or 
laboratory parameters measured, confirming the same efficacy of bolus therapy as in case of 
conventional administration. 
The widespread use of corticosteroids has been associated with an increased incidence of a 
variety of adverse effects involving the musculoskeletal, the endocrine, the metabolic system, 
neuropsychiatric wellbeing, the GI system, the skin, eyes, infectious risk, the cardiovascular and 
the hematological system (164). Dosage and duration of therapy are some of the most important 
factors influencing the development of the toxic effects of corticosteroids. Although no data is 
available on the harmful effects of short term corticosteroid therapy on lipid and bone 
metabolism, our results revealed that short-term use of steroids increases BMI and body fat 
percent and decrease bone density. Common adverse effects of short term therapy include moon 
face, mood changes, insomnia, GI intolerance, weakness, fluid retention, weight gain, increased 
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appetite, increased infections, amenorrhea, elevated blood glucose, slow wound healing, striae, 
and acneiform rash. Alternate-day steroid therapy may decrease hypothalamic-pituitary- adrenal 
axis suppression and therefore the development of certain side effects (165). However, in this 
study, the most common side effects occurred more frequently in patients with conventional vs. 
bolus-administration steroid therapy. 
Osteoporosis is present in 30–45% of patients with CD, and its rate is somewhat lower in patients 
with UC (166, 167). Osteopenia is likely related to the chronic inflammatory process itself, and 
furthermore triggered by steroid use. Steroid related osteoporosis is multifactorial; decreased 
calcium absorption, development of secondary hyperparathyroidism, stimulating osteoclast 
activity, and decrease osteoblast production are only some of the potential etiological factors 
(168). Hyperlipidaemia is also a common side effect of steroid therapy (169).  Steroids are 
supposed to influence lipid metabolism by redistributing body fat and facilitating of effects of 
lipolytic agents. Large doses of glucocorticoids lead to redistribution of fat to the upper trunk and 
face, with a concomitant loss of fat in the extremities (170). Our result revealed beneficial effect 
of bolus-administered corticosteroid therapy on bone density and body fat percent. 
Side effects related to lipid metabolism are presented in patients on cyclosporin A therapy also. 
Cyclosporine is one of the most effective therapeutic choices for patients with severe, refractory 
UC (84). Cohen et al. investigated (171) the quality of life of 42 patients with severe UC and 
found that patients who underwent colectomy assessed their own quality of life and health status 
to be worse than those who had been treated with cyclosporine. However, the frequent 
occurrence of side effects may limit the use of CyA in the treatment of UC. Although 72.2% of 
our patients developed side effects, none of these proved to be life-threatening. It should be noted 
that CyA had to be discontinued due to intolerable severe side effects in 29.2% of the patients. 21 
patients developed intolerable side effects; one achieved remission and 3 of the 21 patients had 
loss of response. Our findings suggest that CyA therapy may result in increased serum cholesterol 
levels even in the long-term, after discontinuation of the therapy (Figure 5). 
Although most of the adverse effects associated with the use of CyA are dose-dependent, the 
study of van Assche et al. did not find any significant difference between the low-dose (2 mg/kg) 
and the high-dose (4 mg/kg) group with regard to cyclosporine-associated adverse effects (172). 
In addition, oral administration is recommended after the acute period to minimize the risk of 
developing side effects (173). In the acute phase of our study, CyA was administered 
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intravenously and in cases of good initial response, orally, with azathioprine treatment added in 
some cases (174). CyA was administered with a mean oral dose of 4.7 mg/kg.  
Nephrotoxicity and hepatotoxicity are common and severe side effects of CyA therapy, but minor 
side effects also occur frequently during the therapy. Lichtiger et al. revealed (175) that the most 
common adverse reactions in UC patients treated with CyA were paraesthesia and hypertension. 
Both symptoms were also detected in our cohort; paraesthesia occurred in 4, hypertension in 11 
patients. In addition, 10 of our UC patients experienced tremor, 7 had hypertrichosis and 11 noted 
myalgia or muscle cramping. Weber et al. reported (176) similar adverse reactions and the 
occurrence of infections, as well. Ten out of 19 patients developed side effects (2 of them had 
high serum creatinine levels, 1 had hypertension, 5 had tremor, 1 had hirsutism and 1 had 
gingival hyperplasia), two patients had systemic CMV infection, and one also had a herpes virus 
infection and oesophageal candidiasis. Although no prophylactic antimicrobial treatment was 
administered during the CyA therapy, the incidence of infections was low: only viral infection 
occurred in 3 cases (4.2%).  
Nevertheless, there are limited data about the long-term effects of CyA therapy on the lipid 
profile. In our study, serum total cholesterol, triglyceride and creatinine levels before, during and 
after CyA therapy were compared in severe, steroid-refractory UC. Significant increase was 
found only in serum cholesterol levels during and after discontinuation of the CyA therapy. 
However, the control group did not experience the same results. Kuster et al. (177) reported that 
serum levels of CyA correlate significantly with total cholesterol levels, LDL-cholesterol levels, 
the apoB and cholesterol/HDL ratio, but not with triglyceride levels, suggesting that CyA may 
cause atherogenic dyslipidaemia. Other publications also describe similar or identical results 
regarding the relationship between CyA and cholesterol levels (178,179). Spinelli et al. studied 
patients treated with a combination of prednisolone and another immunosuppressive drug such as 
CyA, sirolimus, mycophenolate mofetil, or everolimus (180). The changes in lipid profiles were 
evaluated after 1 year of therapy, and dyslipidaemia was found to be frequent. Patients treated 
with CyA had worse lipid profiles than those in the other treatment groups. No data is available 
about the relationship between hypercholesterolaemia and other drug-related side effects. 
Cyclosporine also has an effect on bile acid metabolism by blocking bile acid synthesis, hepatic 
uptake and secretion. These effects may lead to hyperlipidaemia. Previous trials have shown that 
CyA treatment affects bile salt kinetics and plasma lipid levels. However, corticosteroids 
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affecting the bile salt synthesis could not be excluded (181,182). In our study, we attempted to 
eliminate that effect with the control group treated with infliximab and streroids. Results showed 
higher cholesterol levels in the CyA cohort, as compared to the control group. Regarding the 
correlation between hypertension and increased CyA levels as a side effect, Wang et al. 
suggested that cyclosporine stimulates the renal sodium channel by elevating the level of 
cholesterol (183). Our results showed that hypertension and increased cholesterol levels occurred 
frequently in UC patients treated with CyA.  
Other investigations suggested that the inhibition by CyA leads to dyslipidaemia by reducing 
apolipoprotein A1 gene expression. ApoA1 is a major component of HDL, therefore decreased 
levels of apoA1 result in low levels of HDL. The calcineurin pathway stimulates apoA1 gene 
expression; therefore, by inhibiting this pathway with cyclosporine, apoA1 levels may be reduced 
and as a result, HDL levels may also be reduced (184). Only total serum cholesterol levels were 
assessed in our study. A population-based study suggested that there are no benefits to measuring 
apoB or apoA1 compared with a total cholesterol and HDL cholesterol measurement (185). 
Furthermore, the study of Suk et al. (186) showed that calcineurin has an effect on the cAMP 
signalling pathway and furthermore, indirectly affects protein kinase A activation by regulating 
the phosphodiesterases, which play an important role in the adipokine gene transcription. In 
addition, calcineurin provides short- and long-term regulation to control gene expression and 
function.  
Charco et al. (187) compared the long-term effects of tacrolimus and CyA therapies on serum 
cholesterol levels in liver transplant patients. The average follow-up period was 36 months, and 
the incidence of hypercholesterolaemia was found to be 34.6%. Higher mean cholesterol levels 
were found in the group treated with CyA (p=0.01). At the end of the study, a significant 
difference was found between the steroid and cyclosporine vs. tacrolimus and steroid-free groups. 
In our study, a control group treated with biologicals and steroids was employed to eliminate the 
additive effect of corticosteroids on the serum lipid profile. Results showed that cholesterol levels 
were higher in the CyA group than in the control group, and stayed at an increased level after 
therapy. 
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9. CONCLUSIONS AND NEW RESULTS ESTABLISHED IN THE STUDIES 
RELATED TO THE THESIS 
 
1. Our data showed 40.3% of occurrences of CDP in IBD outpatients, and 51.1% of the patients 
in the relapse cohort were C.difficile-positive. We revealed a significant difference regarding 
CDP between IBD patients in relapse and those in remission (where p<0.001).  Our results 
confirmed an association between previous antibiotic use and CDP. The occurrences of C.difficile 
and Candida positivity were excessively high in patients in an acute relapse, which suggests the 
importance of intestinal microbiota in IBD and an important role in the relapse, therefore stool 
analysis is recommended in flare-ups. FC and MMP-9 has no diagnostic value to differentiate 
between infection-induced and natural relapse.  
2. We discovered that 11.25% of our enrolled patients exhibited skin manifestations associated to 
Blastocystis sp., mainly on the females. The occurrence of Blastocystis sp. was 6% in 
symptomatic patients who required medical attendance in the time period between 2005 and 
2013. We did not find significant difference in eosinophilia between patients with vs. without 
skin manifestations. 73.75% of the patients indicated that they had gastrointestinal symptoms: 40 
patients complained of abdominal pain, 17 with blood in their stool, while other symptoms, such 
as meteorism (15 subjects), weigh loss (8 subjects), perianal pain or itching (6 subjects), passing 
stool with mucus (5 subjects), vomiting (2 subjects) and fever (2 subjects) were less frequent.  
3. The third study revealed that two thirds of the patients agreed to influenza vaccination. Split 
virion vaccines proved to be more effective in the vaccination procedure: post-immunisation 
titres of both subtypes increased significantly after the administration of split virion vaccines 
compared with the controls and with those patients vaccinated with whole virion vaccines. The 
antibody titres of Influenza B also increased significantly in patients immunised with split virion 
vaccine and treated with anti TNF-α therapy. The high number of cases with pre-existing 
antibody levels can be explained with previous vaccinations and prior influenza infections, 
although cross-protection against influenza virus strains could also be present. Although no 
serious side effects were developed after influenza vaccination, influenza-like symptoms in the 
first weeks after immunisation occurred more frequently in patients receiving split virion vaccine. 
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Influenza-like symptoms did not differ significantly between vaccinated vs. control patients 
(8.3% vs. 7.5%). A mild relapse of the disease was observed in only 10% of the patients and was 
more common in vaccinated than in control subjects. In conclusion, our results suggest that IBD 
patients on immunosuppressive therapy are recommended to be immunised with split virion 
vaccines and that measuring the antibody responses is worthwhile in patients treated with 
immunosuppressants to determine the efficacy of influenza vaccination. Larger and more detailed 
studies are needed to compare the efficacy of these vaccinations and to examine the antibody 
response in immunocompromised patients. 
4. Our results suggest that bolus tapering of equivalent doses of methylprednisolone administered 
in conventional daily doses has equivalent clinical efficacy, but more favourable side effect 
profile. As no significant difference was detected between the two administration types on the 
clinical and laboratory parameters of disease activity, it appears that bolus administration of 
corticosteroids can safely and effectively replace the conventional use of methylprednisolone for 
active IBD. Of course, further controlled, randomized trials are needed to confirm these results 
that may revolutionize steroid therapy in IBD. It should be noted, significant changes may 
develop in bone and lipid metabolism during even a short-term steroid therapy. 
5. Serum cholesterol levels showed significant increase during CyA therapy compared to the time 
before use of the drug and to the control cohort of patients being treated with infliximab and 
corticosteroids. This elevation remained significant for a year. Serum cholesterol levels for the 
UC group with adverse events were significantly higher compared to patients who did not 
develop any side effects. Creatinine levels did not change significantly during CyA therapy. In 
the control group, cholesterol, triglyceride and creatinine levels did not change significantly 
during therapy or after its discontinuation. In conclusion, we found increased serum cholesterol 
levels in severe, steroid-refractory UC patients treated with CyA not only during the therapy, but 
also after its discontinuation, suggesting that CyA has a long-term effect on serum lipid 
metabolism. Furthermore, in the presence of other adverse events, cholesterol levels were 
significantly higher, suggesting that drug-related impairment of cholesterol biosynthesis and 
other side effects are rather common, therefore practically speaking, monitoring cholesterol levels 
during CyA therapy is recommended. Considering the high rates of hypercholesterolaemia as a 
side effect of cyclosporine therapy, this topic is worth to be studied further.  
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